<!DOCTYPE html>

<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if gt IE 8]>      <html class="no-js"> <![endif]-->

<!--[if gt IE 8]><!-->
<html class="no-js" prefix="og: http://ogp.me/ns#">
<!--<![endif]-->

<head>
<title>Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer</title>
<meta http-equiv="content-type" content="text/html; charset=UTF-8" />
<meta charset="utf-8" />
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />

<meta name="citation_doi" content="10.3892/ijo.2012.1470" />
<meta name="citation_journal_title" content="International Journal of Oncology" />
<meta name="citation_title" content="Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer" />

	<meta name="citation_author" content="Gil,Eun  Young " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Jo,Uk  Hyun " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Jeong,Hoiseon " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Pathology, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Whang,Young  Mi " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Woo,Ok  Hee " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Radiology, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Cho,Kyu  Ran " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Radiology, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Seo,Jae  Hong " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Kim,Aeree " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Pathology, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Lee,Eun  Sook " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Surgery, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Koh,Insong " />
	<meta name="citation_author_institution" content="Department of Physiology, College of Medicine, Hanyang University, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Kim,Yeul  Hong " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea" />

	<meta name="citation_author" content="Park,Kyong  Hwa " />
	<meta name="citation_author_institution" content="Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea" />


<meta name="citation_publication_date"
	content="2012-08-01" />
<meta name="citation_volume" content="41" />
<meta name="citation_issue" content="2" />
<meta name="citation_firstpage" content="611" />
<meta name="citation_lastpage" content="620" />
<meta name="citation_publisher" content="Spandidos Publications" />
<meta name="citation_issn" content="1019-6439" />
<meta name="citation_abstract_html_url" content="http://www.spandidos-publications.com/10.3892/ijo.2012.1470/abstract" />
<meta name="citation_pdf_url" content="http://www.spandidos-publications.com/10.3892/ijo.2012.1470/download" />
<meta name="citation_fulltext_world_readable" content="" />

<meta name="keywords"
	content="cancer, oncology, oncogene, molecular medicine, tumor, apoptosis, gene, cell, research, scientific journals, tumour suppressor genes, cell cycle, growth factors" />
<meta name="verify-v1"
	content="qIInQfvSmbVNPO1nn+hEr0GnchYI4j93np2wrWGr29A="></meta>
<meta name="verify-v1"
	content="KOd/fzGN2I+RDbonO/qYB3yaji9QcOddBCxBKx+5j9U="></meta>
	
	
 <meta name="twitter:card" content="summary"></meta>
 <meta name="twitter:title" content="Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer"></meta>
 <meta name="twitter:site" content="https://www.spandidos-publications.com/10.3892/ijo.2012.1470"  />
 <meta name="twitter:image" content="https://www.spandidos-publications.com/resources/images/ijo.jpg"/>	
 <meta name="twitter:description" content="Docetaxel is one of the most commonly used chemotherapeutic agents in breast cancer. To avert from significant toxicities with no clinical benefit, identification of predictive markers for response is one of the most important unsolved clinical needs. Therefore, the potential associations of RASSF1A hypermethylation and response to docetaxel-based chemotherapy were evaluated, and the underlying mechanism was studied. The expression of RASSF1A in breast cancer cell lines and tissues of normal breast, ductal carcinoma in situ (DCIS), and breast cancer (n=45) was analyzed by immunohistochemistry and western blot analysis. Immunohistochemical staining showed that the expression of RASSF1A was frequently lost in primary breast cancers and human breast cancer cell lines, while normal breast tissues or DCIS displayed moderate to strong expression. Furthermore, quantitative methylation analysis of the RASSF1A promoter region in 45 primary breast cancers revealed that RASSF1A was frequently methylated in primary breast cancers (≥20% methylation in 53% of the patients), and prospective analysis in patients with locally advanced or recurrent breast cancer showed that the mean level of methylation of RASSF1A was significantly higher in patients who did not respond to docetaxel-based chemotherapy (30.6±8.5%) than patients with partial or complete response (20.1±11.2%, p=0.042). Finally, in vitro studies showed that RASSF1A had cooperative activity in suppression of cancer cell growth and proliferation by enhancing docetaxel-induced cell cycle arrest. Our results suggest that hypermethylated RASSF1A is an important modulating factor for the efficacy of docetaxel-based chemotherapy in breast cancer.
"/>	
 

 <meta property='og:title' content="Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer"/>
 <meta property='og:image:secure_url' content="https://www.spandidos-publications.com/resources/images/ijo.jpg"/>
 <meta name="image" property='og:image' content="https://www.spandidos-publications.com/resources/images/ijo.jpg"/>
 <meta property="og:image:width" content="200" /> 
 <meta property="og:image:height" content="200" />
 <meta property="og:image:type" content="image/jpg" />
 <meta property='og:description' content="Docetaxel is one of the most commonly used chemotherapeutic agents in breast cancer. To avert from significant toxicities with no clinical benefit, identification of predictive markers for response is one of the most important unsolved clinical needs. Therefore, the potential associations of RASSF1A hypermethylation and response to docetaxel-based chemotherapy were evaluated, and the underlying mechanism was studied. The expression of RASSF1A in breast cancer cell lines and tissues of normal breast, ductal carcinoma in situ (DCIS), and breast cancer (n=45) was analyzed by immunohistochemistry and western blot analysis. Immunohistochemical staining showed that the expression of RASSF1A was frequently lost in primary breast cancers and human breast cancer cell lines, while normal breast tissues or DCIS displayed moderate to strong expression. Furthermore, quantitative methylation analysis of the RASSF1A promoter region in 45 primary breast cancers revealed that RASSF1A was frequently methylated in primary breast cancers (≥20% methylation in 53% of the patients), and prospective analysis in patients with locally advanced or recurrent breast cancer showed that the mean level of methylation of RASSF1A was significantly higher in patients who did not respond to docetaxel-based chemotherapy (30.6±8.5%) than patients with partial or complete response (20.1±11.2%, p=0.042). Finally, in vitro studies showed that RASSF1A had cooperative activity in suppression of cancer cell growth and proliferation by enhancing docetaxel-induced cell cycle arrest. Our results suggest that hypermethylated RASSF1A is an important modulating factor for the efficacy of docetaxel-based chemotherapy in breast cancer.
"/>	
 <meta property='og:url' content="https://www.spandidos-publications.com/10.3892/ijo.2012.1470"/>

<link rel="stylesheet" type="text/css" media="all"
	href="/resources/css/styles.css" />
<link rel="stylesheet" href="/resources/css/jquery.fancybox.css"
	type="text/css" />

<!--[if IE 7]>  <link rel="stylesheet" type="text/css" href="/resources/css/ie7.css"> <![endif]-->
<script src="/resources/js/modernizr-3.3.1.min.js"
	type="text/javascript"></script>

</head>

<body class="ijo">

	<!--[if lt IE 7]>
        <p class="chromeframe">You are using an outdated browser. <a href="http://browsehappy.com/">Upgrade your browser today</a> or <a href="http://www.google.com/chromeframe/?redirect=true">install Google Chrome Frame</a> to better experience this site.</p>
    <![endif]-->

	
	
	<div class="wrapper">

		<div>
		<div class="super wide d-flex pb-4">
			<div class="super fixed_width">
				<ul  >
					<li><a href="/home">Home</a></li>
					
					
					<li><a href="/osats">Submit Manuscript</a></li>
					<!-- <th:block th:if="${session != null and session.user != null and session.user.type == 'user'}"> 
						<li th:if="${session.user.maxYearlyReviews} gt 0" ><a href="/reviews">Reviews</a></li>
					</th:block> -->
					<li><a href="/myaccount">My Account</a></li>
				</ul>			
			</div>
		</div>
	
		<div class="header wide">
			<div class="header fixed_width">
				<div class="header_logo">
					<a href="/home"><img src="/resources/images/spandidoslogo.png"/></a>
				</div>

				<div class="header_search">

					<div id="searchbtn">
						<a href="/advancedsearch/ijo">Advanced Search</a>
						
					</div>
					
					<div  class="searchbox">
							
							<a href="javascript:BasicSearch(&#39;ijo&#39;)"   ><img  src="/resources/images/searchbutton.png"/></a>
							
							<input class="" type="text" id= "searchFor" />		
					</div>
					
					<div> 
						
						
						<ul >
							<li><a href="/register">Register</a></li>
							<li><a href="/login" id="loginLink">Login</a></li>							
						</ul>
						
						
						
					</div>		
					
					
					
				</div>
				<div class="header_nav">
					<ul>
						<li style="width: 8.3%;" class="ol"><a href="/ol">Oncology <br />Letters</a></li>
						<li style="width: 8.3%;" class="ijo"><a href="/ijo">International <br />Journal <br />of Oncology</a></li>
						<li style="width: 8.3%;" class="mco"><a href="/mco">Molecular <br />and Clinical <br />Oncology</a></li>
						<li style="width: 8.3%;" class="etm"><a href="/etm">Experimental <br />and Therapeutic <br />Medicine</a></li>
						<li style="width: 8.3%;" class="ijmm"><a href="/ijmm">International <br />Journal <br />of Molecular <br />Medicine</a></li>
						<li style="width: 8.3%;" class="br"><a href="/br">Biomedical <br />Reports</a></li>
						<li style="width: 8.3%;" class="or"><a href="/or">Oncology <br />Reports</a></li>
						<li style="width: 8.3%;" class="mmr"><a href="/mmr">Molecular <br />Medicine <br />Reports</a></li>						
						<li style="width: 8.3%;" class="wasj"><a  href="/wasj">World Academy <br />of Sciences <br />Journal</a></li>
						<li style="width: 8.3%;" class="ijfn"><a  href="/ijfn">International <br />Journal <br />of Functional<br />Nutrition</a></li>
						<li style="width: 8.3%;" class="ije"><a  href="/ije">International <br />Journal <br />of Epigenetics</a></li>
						<li style="width: 8.3%;" class="mi"><a  href="/mi">Medicine <br />International </a></li>
					</ul>
				</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
			</div>
		</div>
		
		<!-- Journal and Article pages show Journal banner -->
		<div class="banner wide flex">
			<div class="banner fixed_width">
				
				<h1>International<br/>Journal of<br />Oncology</h1>
				
				
				
				
				
				
				
				
				
				
				<img src="/resources/images/bannerijo.jpg" alt="Journal Banner" />
			</div>
		</div>		
	</div>

		<div class="content wide">
			<div class="content fixed_width">
				<div class="content_sidebar">
				<ul class="sidebar_journal_top">
					<li class="sidebar_title"><a href="/ijo">Journal Home</a></li>
					<li >
						<a href="/ijo">Current Issue</a>
					</li>
					<li>
						
						<a href="/ijo/forthcoming">Forthcoming Issue</a>
					</li>
					<li>
						<a id="toggleSpecialIssue" href="#" onclick="$('.toggleSpecialIssue').toggle();return false;">Special Issues</a>
						<ul class="toggleSpecialIssue" style="display:none; margin-bottom: 0px; border:0px ">
							<li><a href="/ijo/specialIssues/open">Open Special Issues</a></li>
							
							<li><a href="/pages/ijo/specialissues">About Special Issues</a></li>
							<li><a href="/osats">Submit Paper</a></li>
						</ul>
					</li>
					
					<li><a href="/ijo/mostread">Most Read</a></li>
					<li>
						<a id="toggleMostCitedDimensions" href="#" onclick="return false">Most Cited (Dimensions)</a>
						<ul class="toggleMostCitedDimensions" style="display:none; margin-bottom: 0px; border:0px ">
							<li><a href="/ijo/mostciteddimensionrecent">Past Two Years</a></li>
							<li><a href="/ijo/mostciteddimension">Total</a></li>
						</ul>
					</li>
					<li><a id="toggleMostCitedCrossRef" href="#" onclick="return false">Most Cited (CrossRef)</a>
						<ul class="toggleMostCitedCrossRef" style="display:none; margin-bottom: 0px; border:0px ">
							<li><a href="/ijo/mostcitedbylastyear">Past Year <span  class="rightsReservedCrossref">0 </span></a></li>
							<li><a href="/ijo/mostcitedby">Total</a></li>
						</ul>
					</li>
					<li><a id="toggleSM" href="#toggleSM" onclick="return false">Social Media</a>
						<ul class="toggleSM" style="display:none; margin-bottom: 0px; border:0px ">
							<li><a class="medium" href="/ijo/1m/mostaltmetricmentions">Past Month</a></li>
							<li><a class="medium" href="/ijo/1y/mostaltmetricmentions">Past Year</a></li>
							<li><a class="medium" href="/ijo/at/mostaltmetricmentions">Total</a></li>
						</ul>
					</li>
					 <li><a href="/ijo/archive">Archive</a></li>
				</ul>
				<ul class="sidebar_journal_bottom">
					<li class="sidebar_title">Information</li>
					<li><a href="/osats">Online Submission</a></li>
					<li><a href="/pages/ijo/info_for_authors">Information for Authors</a></li>
					<li><a href="/languageediting">Language Editing</a></li>
					<li><a href="/pages/info_for_reviewers">Information for Reviewers</a></li>
					<li><a href="/pages/ijo/editorialPol">Editorial Policies</a></li>
					
					<li>
						
						<a href="/pages/ijo/editorial">Editorial Academy</a>
						
					</li>
					<li>
						
						<a href="/pages/join_editorial">Join Editorial Academy</a>
						
					</li>
					
					<li><a href="/pages/ijo/aims_scope">Aims and Scope</a></li>
					<li><a href="/pages/ijo/abstracting" id="abstracting" class="staticContent">Abstracting and Indexing</a></li>
					<li><a href="/pages/ijo/bibliographic">Bibliographic Information</a></li>
					<li><a href="/pages/info_for_librarians">Information for Librarians</a></li>
					<li><a href="/pages/info_for_advertisers">Information for Advertisers</a></li>	
					<li><a href="/pages/reprints">Reprints and permissions</a></li>						
					<li><a href="/pages/ijo/contact">Contact the Editor</a></li>
				</ul>
				
				<ul class="sidebar_journal_bottom">
						<li class="sidebar_title">General Information</li>
						<li><a href="/pages/about">About Spandidos</a></li>
						<li><a href="/pages/conference">Conferences</a></li>
						<li><a href="/pages/jobs">Job Opportunities</a></li>
						<li><a href="/pages/contact">Contact</a></li>
						<li><a href="/pages/terms">Terms and Conditions</a></li>
				 </ul>	
			</div>

				<div class="content_main">
					<div class="content_article">
					
					
						

						

						

						

						
							<h1 id="titleId">Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer</h1>
						

						<ul class="article_details">
						
						    
						
							<li><span class="bold">Authors:</span>
								<ul id="authorshipNames">
									
										
										<li>Eun  Young  Gil</li>
									
										
										<li>Uk  Hyun  Jo</li>
									
										
										<li>Hoiseon  Jeong</li>
									
										
										<li>Young  Mi  Whang</li>
									
										
										<li>Ok  Hee  Woo</li>
									
										
										<li>Kyu  Ran  Cho</li>
									
										
										<li>Jae  Hong  Seo</li>
									
										
										<li>Aeree  Kim</li>
									
										
										<li>Eun  Sook  Lee</li>
									
										
										<li>Insong  Koh</li>
									
										
										<li>Yeul  Hong  Kim</li>
									
										
											
												<li class="corresponding"
													title="khpark@korea.ac.kr">Kyong  Hwa  Park</li>
											
										
										
									
								</ul>
							</li>

							<li><p>
									<a class="bold" href="#" id="toggle">View Affiliations</a>
								</p>

								<div class="toggle" style="display: none;">
									<br /> <span class="bold">Affiliations: </span><span>Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea, Division of Oncology/Hematology, Department of Pathology, Korea University College of Medicine, Seoul, Republic of Korea, Division of Oncology/Hematology, Department of Radiology, Korea University College of Medicine, Seoul, Republic of Korea, Division of Oncology/Hematology, Department of Surgery, Korea University College of Medicine, Seoul, Republic of Korea, Department of Physiology, College of Medicine, Hanyang University, Seoul, Republic of Korea</span>
								</div></li>

							<!--<li><span class="bold">Corresponding author:</span> <span th:text="${dispArt.correspondingList}">Author name</span></li>-->
							<li><span class="bold">Published online on:</span> <span
								id="publishedOn">May 10, 2012</span> <span>&nbsp;&nbsp;&nbsp;</span> <span
								id="doi">https://doi.org/10.3892/ijo.2012.1470</span>
							</li>

							<li>
								
									<span  class="bold">Pages: </span>
									<span>611-620</span>
								
								
								
								</li>

							
						</ul>



						<div>

							<div id="metrics">
								<div>
									<span title="The metrics are calculated only from this site"
										class="bold">Metrics: </span> <span class="small"
										title="The metrics are calculated only from this site">Total
										Views: </span> <span
										title="The metrics are calculated only from this site"
										class="bold small" id="postTotalFullArticleViews">0 </span> <span
										class="small">(Spandidos Publications:</span> <span
										class="bold small" id="postFullArticleViews"></span> <span
										class="small"> | PMC Statistics: </span> <span
										class="bold small" id="postPMCFullArticleViews"></span> <span
										class="small">)</span>

									<div>
										<span style="visibility: hidden;"
											title="The metrics are calculated only from this site"
											class="bold">Metrics: </span> <span
											title="The metrics are calculated only from this site"
											class="small">Total PDF Downloads: </span> <span
											title="The metrics are calculated only from this site"
											id="postTotalArticleDownloads" class="bold small">0 </span> <span
											class="small">(Spandidos Publications:</span> <span
											class="bold small" id="postArticleDownloads"></span> <span
											class="small"> | PMC Statistics: </span> <span
											class="bold small" id="postArticlePMCDownloads"></span> <span
											class="small">)</span>
									</div>

								</div>



							</div>
							<div>
								<span id="citationCountId"> <a class="citedByCountId"
									style="margin-left: 0px"
									href="/getTotalCount/10.3892/ijo.2012.1470"></a>
								</span>
								<span id="citation"> <a class="citedBy"
									style="margin-left: 0px"
									href="/citationhtml/10.3892/ijo.2012.1470/html">
										Cited By (CrossRef): </a>
								</span> <span class="bold small" id="citationCount">0</span> <span
									class="bold small"> citations </span>
								<span class="bold small citationAllArticlesClass" id="citationAllArticlesId">
									<a id="citedByIdViewArticles" class="citedBy"
									style="font-size: 15px; text-decoration: none; margin-left: 0px"
									href="/citationhtml/10.3892/ijo.2012.1470/html">
										Loading Articles... </a>
								</span> 
							</div>

							<a class="moreLikeThis" style="display: none"
								href="/morelikethis/23288"></a>

							<div id="citationDiv" style="display: none">
								<h4>This article is mentioned in:</h4>
								<div id="citations"></div>
							</div>

							<span class="__dimensions_badge_embed__"
								data-hide-zero-citations="true" data-legend="always"
								data-style="small_circle" data-doi="10.3892/ijo.2012.1470"></span>
							<script async="async" src="https://badge.dimensions.ai/badge.js"
								charset="utf-8"></script>
							<br></br> <span data-hide-no-mentions="true"
								data-badge-details="right" class='altmetric-embed'
								data-badge-type="donut" data-link-target="_blank" data-doi="10.3892/ijo.2012.1470"></span>
						</div>


						<h4>Abstract</h4>

						


						<div
							id = "articleAbstract">Docetaxel is one of the most commonly used chemotherapeutic agents in breast cancer. To avert from significant toxicities with no clinical benefit, identification of predictive markers for response is one of the most important unsolved clinical needs. Therefore, the potential associations of RASSF1A hypermethylation and response to docetaxel-based chemotherapy were evaluated, and the underlying mechanism was studied. The expression of RASSF1A in breast cancer cell lines and tissues of normal breast, ductal carcinoma in situ (DCIS), and breast cancer (n=45) was analyzed by immunohistochemistry and western blot analysis. Immunohistochemical staining showed that the expression of RASSF1A was frequently lost in primary breast cancers and human breast cancer cell lines, while normal breast tissues or DCIS displayed moderate to strong expression. Furthermore, quantitative methylation analysis of the RASSF1A promoter region in 45 primary breast cancers revealed that RASSF1A was frequently methylated in primary breast cancers (≥20% methylation in 53% of the patients), and prospective analysis in patients with locally advanced or recurrent breast cancer showed that the mean level of methylation of RASSF1A was significantly higher in patients who did not respond to docetaxel-based chemotherapy (30.6±8.5%) than patients with partial or complete response (20.1±11.2%, p=0.042). Finally, in vitro studies showed that RASSF1A had cooperative activity in suppression of cancer cell growth and proliferation by enhancing docetaxel-induced cell cycle arrest. Our results suggest that hypermethylated RASSF1A is an important modulating factor for the efficacy of docetaxel-based chemotherapy in breast cancer.
</div>

						<div>
							<div>



<h4>Introduction</h4>
<p>Breast cancer is one the most common cancers in
women worldwide as well as in Korea (<a href="#b1-ijo-41-02-0611" class="linksColor">1</a>). Although treatment outcome of breast
cancer has been greatly improved due to early diagnosis and
development of various targeted agents, prognosis of patients with
locally advanced breast cancer still remains to be improved.
Recently, neoadjuvant chemotherapy has increasingly been
considered, since the chance for breast conservation is
significantly increased and the treatment outcome was similar to
that in patients who received adjuvant chemotherapy after primary
surgery (<a href="#b2-ijo-41-02-0611" class="linksColor">2</a>,<a href="#b3-ijo-41-02-0611" class="linksColor">3</a>). Therefore, it is critical to identify
biologic markers for response to commonly used chemotherapeutic
agents in a neoadjuvant setting. To date, several studies have been
conducted for the identification of the predictive markers for
response to neoadjuvant chemotherapy, and some biologic
characteristics of tumors such as hormone receptor status, HER-2
overexpression, and Ki-67 labeling index have been suggested as
potential biomarkers (<a href="#b4-ijo-41-02-0611" class="linksColor">4</a>,<a href="#b5-ijo-41-02-0611" class="linksColor">5</a>). However, none of these has been
proposed as a marker based on the biologically relevant mechanisms
in their cytotoxicity for a specific chemotherapeutic agent. Thus,
the multi-factorial molecular mechanisms determining chemotherapy
response remain largely unclear.</p>
<p>Taxanes, including docetaxel, in combination with
other cyctotoxic agents or targeted agents are the standard
treatment for locally advanced or metastatic breast cancers. Many
clinical trials have demonstrated the efficacy of the taxanes in
this group of patients, however, about 20% of breast cancers do not
shrink significantly or progress with neoadjuvant treatment and
30–40% of the patients who had residual disease ultimately get
recurrent cancer (<a href="#b2-ijo-41-02-0611" class="linksColor">2</a>,<a href="#b3-ijo-41-02-0611" class="linksColor">3</a>). Therefore, identification of promising
biomarker which can guide physicians to select best treatment
regimen is clearly unmet need in this era of personalized care.</p>
<p>In breast cancers, multitudes of genes are known to
be suppressed by epigenetic mechanisms in the promoter region, and
<span class="italic">RASSF1A</span> is one of the most frequently silenced genes in this
type of cancer (<a href="#b6-ijo-41-02-0611" class="linksColor">6</a>). Moreover,
inactivation of the RASSF1A gene by the methylation is known as an
early event in the carcinogenesis of breast cancer (<a href="#b7-ijo-41-02-0611" class="linksColor">7</a>–<a href="#b9-ijo-41-02-0611" class="linksColor">9</a>), and
recent studies have suggested detection of methylated
<span class="italic">RASSF1A</span> in serum or body fluids as a biomarker for early
breast cancer development (<a href="#b9-ijo-41-02-0611" class="linksColor">9</a>–<a href="#b11-ijo-41-02-0611" class="linksColor">11</a>).
Furthermore, there is a growing amount of data, demonstrating that
methylation status in the promoter region of <span class="italic">RASSF1A</span> is
associated with poor prognosis in breast cancer patients (<a href="#b12-ijo-41-02-0611" class="linksColor">12</a>–<a href="#b14-ijo-41-02-0611" class="linksColor">14</a>)
as well as patients with other cancers (<a href="#b15-ijo-41-02-0611" class="linksColor">15</a>–<a href="#b18-ijo-41-02-0611" class="linksColor">18</a>).
Epigenetic or genetic modification of RASSF1A gene may have effects
on key biological processes including apoptosis, cell cycle
regulation, mitosis, and microtubule dynamics in cancer cells,
which have been shown in numerous studies (<a href="#b19-ijo-41-02-0611" class="linksColor">19</a>–<a href="#b22-ijo-41-02-0611" class="linksColor">22</a>).
Our recent data showed that RASSF1A protein enhances
microtubule-targeted drugs in inducing G2/M arrest in non-small
cell lung carcinoma (NSCLC) cells (<a href="#b23-ijo-41-02-0611" class="linksColor">23</a>), implicating <span class="italic">RASSF1A</span> in
cytotoxicity of anti-mitotic drugs. However, only a few studies
have thus far been focused on the biologic consequence of the
methylation of <span class="italic">RASSF1A</span> in various cancer types (<a href="#b24-ijo-41-02-0611" class="linksColor">24</a>,<a href="#b25-ijo-41-02-0611" class="linksColor">25</a>),
but not in breast cancer. Therefore, we hypothesized that
commonly-silenced <span class="italic">RASSF1A</span> in breast cancer can modulate the
response to the frequently used cytotoxic agent, docetaxel.</p>
<p>To this end, we prospectively investigated the
relationship between the methylation level of RASSF1A gene and
response to docetaxel-based chemotherapy in patients with locally
advanced or recurrent breast cancer using methylation-specific
pyrosequencing analysis, and found that the mean level of
methylation in the promoter region of <span class="italic">RASSF1A</span> showed a
significant association with response to docetaxel-based
chemotherapy. Further <span class="italic">in vitro</span> study showed that
<span class="italic">RASSF1A</span> had cooperative activity in suppression of cancer
cell growth and proliferation by enhancing docetaxel-induced cell
cycle arrest.</p>


<h4>Materials and methods</h4>

<h5>Cell culture and transfection</h5>
<p>Three human breast cancer cell lines, ZR-75-1,
MDA-MB-231, and MCF-7 cells, were obtained from the Korean Cell
Line Bank (Seoul, Korea). For transfection, cells were transiently
transfected with 1 μg of RASSF1A DNA (kindly provided by Dr S.
Tommasi of the Beckman Research Institute, Duarte, CA, USA) or the
empty pcDNA 3.1 plasmid using the Lipofectamine reagent
(Invitrogen, Carlsbad, CA, USA). To generate cells stably
expressing RASSF1A, cells were transfected and selected in
geneticin (G418) (Life Technologies Inc., Grand Island, NY, USA).
Only low passage cells (passage &lt;10) were used for
experiments.</p>


<h5>Patients and tissues</h5>
<p>A total of 45 primary breast cancer tissues were
obtained from newly diagnosed breast cancer patients who were
scheduled to receive docetaxel-based chemotherapy for locally
advanced or metastatic disease. Ten non-cancer tissues were
obtained from 5 patients with DCIS and 5 normal breast tissues from
reduction mammoplasty. All patients gave their informed consent,
and the study was approved by the Ethics and Scientific Committees
of our Institution (no. 2008–267). Tissues were processed and
stored as frozen block at −80°C or paraffin-embedded block in Korea
Lung Tissue Bank (Seoul, Korea) until analysis. Clinicopathological
data involving age, TNM stage, tumor grade, ER/PR/HER-2 expression
status, and response to docetaxel-based chemotherapy were
collected. Responders in this study were defined as the patients
who achieved a partial or complete response to chemotherapy,
according to the RECIST criteria version 1.1 (<a href="#b26-ijo-41-02-0611" class="linksColor">26</a>).</p>


<h5>Cell proliferation assays</h5>
<p>Cell proliferation was assessed by both colorimetric
MTT assay and [<span class="superscript">3</span>H]-thymidine incorporation. Thus, each
breast cancer cell line was incubated with docetaxel for 48 h after
24 h of serum starvation. For the MTT assay, the cells were
incubated for 4 h with MTT reagent and then lysed in 50%
dimethylformamide (DMSO) and 20% SDS-PAGE at 37°C. Optical
densities (OD) at 550 and 670 nm were measured using a plate reader
(BioRad, Hercules, CA, USA), and differential OD between 550 and
670 nm (OD 550–670 nm) was determined. For
[<span class="superscript">3</span>H]-thymidine incorporation assay, 1 μl of
[<span class="superscript">3</span>H]-thymidine (Amersham, Buckinghamshire, UK) was added
per well and plates were incubated for 18 h. Then, cells were
harvested in a cell harvester, and radioactivity (dpm) was counted
using a β-counter. The results were expressed as dpm/mg protein or
as percentage of the control (defined as 100%).</p>


<h5>Methylation-specific PCR (MSP)
analysis</h5>
<p>Genomic DNA was extracted from control,
5-aza-deoxycytidine-treated (10 μM for 3 days) cells using
QIAamp<span class="superscript">®</span> DNA Blood Mini Kit (Qiagen, Valencia, CA, USA),
by following the manufacturer’s instructions. Bisulfite
modification of DNA (1 μg) was performed using the EZ DNA
Methylation-Gold kit™ (Zymo Research, Orange, CA, USA). Based on
the promoter sequence of <span class="italic">RASSF1A</span>, methylation- and
unmethylation-specific primers were designed using Serologicals
CpGware software (<a href="http://apps.serologicals.com/CPGWARE/dna_form2.html" class="linksColor">http://apps.serologicals.com/CPGWARE/dna_form2.html</a>)
methylated, 5′-GCTAAC AAACGCGAACCG-3′; 5′-GGGTTTTGCGAGAGCGCG-3′ and
unmethylated, 5′-CACTAACAAACACAAAC CAAAC-3′;
5′-GGTTTTGTGAGAGTGTGTTTAG-3′; product sizes 169 and 169 bp,
respectively (PMID: 11333291). Bisulfite-modified DNA (2 μl out of
10 μl elute) was used for each PCR. All experiments were performed
in triplicate and repeated at least three times.</p>


<h5>Quantitation of RASSF1A promoter
methylation by pyrosequencing</h5>
<p>Bisulfite-treated DNA from tumors was used for PCR
amplifications. Pyrosequencing was performed using the PSQ96ID
system (Qiagen) including PyroMark Gold Q96 reagents. Primers were
designed by the PyroMark Assay design 2.0 (Qiagen). The primers
amplify a stretch of the <span class="italic">RASSF1A</span> exon 1 (Ensemble ID:
ENST00000266020). The primers target CpG regions within this
stretch. PCR was carried out using 2 μl bisulfite-treated DNA under
the following conditions: 94°C for 5 min, 45x (94°C for 30 sec,
55°C for 30 sec, 72°C for 30 sec), 72°C for 5 min. Intactness of
the PCR product was assessed by electrophoresis on 2% agarose gel
(Seakem<span class="superscript">®</span> LE Agarose, Lonza) and subsequent ethidium
bromide staining. The pyrosequencing primers target a 46-nt
segment, which lies within the previously amplified stretch of
RASSF1A exon 1 and contains 7 CpGs(GTCGGGGTTCGTTTTGTGGTTTCGTTCGG TTCGCGTTTGTTAGCGT).</p>


<h5>Immunohistochemistry and
immunofluorescence</h5>
<p>Expression of RASSF1A protein in tissue samples and
breast cancer cell lines were determined with anti-RASSF1A
monoclonal antibody (clone eB114, eBioscience, Minneapolis, MI,
USA) as previously described (<a href="#b27-ijo-41-02-0611" class="linksColor">27</a>). The staining results were evaluated
according to the immunodetection of stain intensity and amounts of
positive cells by two pathologists (A.K. and H.J.), who discussed
each case until they reached a consensus. The degree of staining
was subdivided as follows: the stain intensity could be from 0 to 3
(0, no staining; 1, focal or fine granular, weak staining; 2,
linear or cluster, strong staining; and 3, diffuse, intense
staining); and the positive cells in the observed breast tissue
samples ranged from 0 to 3 in percentage (0, no staining; 1,
&lt;30%; 2, 30–70%; and 3, &gt;70%). The samples were scored by
their summation: 0–1 (-); 2–3 (+); 4 (++); 5–6 (+++). Any staining
score 2 or above (+) was considered as positive expression.</p>
<p>For immunofluorescence, cells were plated on 18 mm
coverslips and treated on the next day with 10 μM
5-aza-deoxycytidine (Sigma Co., St. Louis, MO, USA). After 48-h
treatment, cells were fixed with 4% paraformaldehyde, permeabilized
in 0.25% Triton X-100 in PBS, and blocked in PBS/5% BSA. RASSF1A
was detected using anti-RASSF1A (eBioscience) followed by
incubation with fluorescent conjugated secondary antibodies
(Molecular Probes, Eugene, OR, USA). After washing, cells were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma
Co.), mounted on glass slides, and examined by a DP40 (Olympus,
Tokyo, Japan).</p>


<h5>Western blot analysis</h5>
<p>The expressions of proteins were detected using
relevant antibodies (anti-RASSF1A, Cdk1, Cdk2, Cdk4, cyclin B, Cell
Signaling, Boston, MA, USA; anti-cyclin D1, Calbiochem, San Diego,
CA, USA; anti-p21, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The collected cells were lysed with 10 μl of dilution buffer
containing 20 mM 3-morpholinopropanesulfonic acid (pH 7.2), 25 mM
β-glycerophosphate, 5 mM EDTA, 1 mM sodium orthovanadate, 1 mM
dithiothreitol, and protease inhibitors (100 μg/ml
phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, and 1 μg/ml
leupeptin). The total cell lysates were resolved on 8–12% SDS-PAGE
as previouslydescribed (<a href="#b23-ijo-41-02-0611" class="linksColor">23</a>).</p>


<h5>Cell cycle analysis</h5>
<p>The cell cycle distribution was determined by flow
cytometric analysis of propidium iodide (PI) labeled cells. Thus,
cells were seeded at 1x10<span class="superscript">5</span> cells/60-mm plate and treated
with docetaxel. The cells were harvested, fixed in 70% ethanol, and
then stored at −20°C. The cells were then washed twice with
ice-cold PBS and incubated with ribonuclease and PI. Cell cycle was
analyzed by BD FACScan flow cytometry (Becton Dickinson, Franklin
Lakes, NJ, USA) and CellQuest software.</p>


<h5>Statistical analysis</h5>
<p>Mean methylation level of RASSF1A according to the
clinicopathological parameters were analyzed by Student’s t-test. A
logistic regression model was applied to determine whether a factor
was independent predictor of response to chemotherapy in a
multivariate analysis. A two-sided 0.05-level test was determined
for statistical significance. All data analyses were conducted with
SPSS software (SPSS Inc., Chicago, IL, USA).</p>



<h4>Results</h4>

<h5>RASSF1A protein and mRNA expressions are
downregulated in breast cancer cell lines and primary breast
cancers</h5>
<p>Western blot analysis and RT-PCR revealed the loss
of RASSF1A protein and mRNA expression in 3 breast cancer cell
lines (ZR-75-1, MDA-MB-231, MCF-7) (<a href="#f1-ijo-41-02-0611" class="linksColor">Fig. 1A</a>). Next, we evaluated the
expression of RASSF1A using immunohistochemical analysis, and
<a href="#f1-ijo-41-02-0611" class="linksColor">Fig. 1B</a> shows that benign breast
tissues and DCIS tissues were strongly positive for RASSF1A,
whereas invasive ductal carcinoma tissues were negative for RASSF1A
staining. Further analysis of primary invasive ductal carcinoma of
breast revealed that RASSF1A was lost in 27 (60%) out of 45 primary
breast samples (<a href="#t1-ijo-41-02-0611" class="linksColor">Table I</a>), thus
indicating that RASSF1A expression is low or lost in many cases of
primary breast cancer specimens as well as selected breast cancer
cell lines. These results support earlier hypothesis that the loss
of RASSF1A is one of the important events in the breast cancer
carcinogenesis (<a href="#b7-ijo-41-02-0611" class="linksColor">7</a>,<a href="#b8-ijo-41-02-0611" class="linksColor">8</a>).</p><div id="f1-ijo-41-02-0611"><a class="fancybox" data-fancybox-group="figures" href="/article_images/ijo/41/2/IJO-41-02-0611-g00.jpg" title="Figure 1 - Decreased expression of RASSF1A in&#xA;breast cancer. (A) Expression of RASSF1A in 3 breast cancer cell&#xA;lines, determined by western blot analysis and RT-PCR analysis.&#xA;β-actin and GAPDH were used as internal controls. (B) RASSF1A&#xA;protein expression in normal breast, DCIS and invasive ductal&#xA;carcinoma. Brown staining in immunohistochemistry is indicative of&#xA;RASSF1A protein expression (magnification x100)."><div class="panel"><table><tbody><tr><td width="115px"><img class="panel-image" src="/article_images/ijo/41/2/IJO-41-02-0611-g00.jpg"></img></td><td><h4>Figure 1</h4><p class="bold">Decreased expression of RASSF1A in
breast cancer. (A) Expression of RASSF1A in 3 breast cancer cell
lines, determined by western blot analysis and RT-PCR analysis.
β-actin and GAPDH were used as internal controls. (B) RASSF1A
protein expression in normal breast, DCIS and invasive ductal
carcinoma. Brown staining in immunohistochemistry is indicative of
RASSF1A protein expression (magnification x100).</p></td></tr></tbody></table></div></a></div><div class="panel" id="t1-ijo-41-02-0611"><a href="#tb_t1-ijo-41-02-0611" class="fancybox" data-fancybox-group="tables" title="Table I - Correlation between RASSF1A gene&#xA;methylation, protein expression, and clinicopathological&#xA;characteristics of breast cancer patients (n=45)."><table><tbody><tr><td width="115px"><img class="panel-image" src="/images/table-icon.jpg"></img></td><td><h4>Table I</h4><p><b>Correlation between RASSF1A gene
methylation, protein expression, and clinicopathological
characteristics of breast cancer patients (n=45).</b></p></td></tr></tbody></table></a><div style="display:none;"><div id="tb_t1-ijo-41-02-0611"><h4>Table I</h4><p><b>Correlation between RASSF1A gene
methylation, protein expression, and clinicopathological
characteristics of breast cancer patients (n=45).</b></p><table xmlns="http://www.w3.org/1999/xhtml" frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"><a name="d7e1256" id="d7e1256" shape="rect"><!-- named anchor --></a></th><th colspan="3" align="center" valign="bottom" rowspan="1"><a name="d7e1257" id="d7e1257" shape="rect"><!-- named anchor --></a><i>RASSF1A</i>
methylation
<hr /></th><th colspan="3" align="center" valign="bottom" rowspan="1"><a name="d7e1262" id="d7e1262" shape="rect"><!-- named anchor --></a>RASSF1A expression
<hr /></th><th align="center" valign="bottom" rowspan="1" colspan="1"><a name="d7e1265" id="d7e1265" shape="rect"><!-- named anchor --></a></th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1"><a name="d7e1267" id="d7e1267" shape="rect"><!-- named anchor --></a>Clinicopathological
characteristics</th><th align="center" valign="bottom" rowspan="1" colspan="1"><a name="d7e1269" id="d7e1269" shape="rect"><!-- named anchor --></a>Number of patients
(no.)</th><th align="center" valign="bottom" rowspan="1" colspan="1"><a name="d7e1271" id="d7e1271" shape="rect"><!-- named anchor --></a>Level of
methylation (%, mean±SD)</th><th align="center" valign="bottom" rowspan="1" colspan="1"><a name="d7e1273" id="d7e1273" shape="rect"><!-- named anchor --></a>P</th><th align="center" valign="bottom" rowspan="1" colspan="1"><a name="d7e1275" id="d7e1275" shape="rect"><!-- named anchor --></a>Positive (no.)</th><th align="center" valign="bottom" rowspan="1" colspan="1"><a name="d7e1277" id="d7e1277" shape="rect"><!-- named anchor --></a>Negative (no.)</th><th align="center" valign="bottom" rowspan="1" colspan="1"><a name="d7e1279" id="d7e1279" shape="rect"><!-- named anchor --></a>P</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1283" id="d7e1283" shape="rect"><!-- named anchor --></a>Age (years)</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1285" id="d7e1285" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1286" id="d7e1286" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1287" id="d7e1287" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1288" id="d7e1288" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1289" id="d7e1289" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1290" id="d7e1290" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1292" id="d7e1292" shape="rect"><!-- named anchor --></a>  &lt;35</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1294" id="d7e1294" shape="rect"><!-- named anchor --></a>4</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1296" id="d7e1296" shape="rect"><!-- named anchor --></a>17.7±18.7</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1298" id="d7e1298" shape="rect"><!-- named anchor --></a>NS</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1300" id="d7e1300" shape="rect"><!-- named anchor --></a>1</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1302" id="d7e1302" shape="rect"><!-- named anchor --></a>3</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1304" id="d7e1304" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1307" id="d7e1307" shape="rect"><!-- named anchor --></a>  ≥35</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1309" id="d7e1309" shape="rect"><!-- named anchor --></a>41</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1311" id="d7e1311" shape="rect"><!-- named anchor --></a>21.7±16.6</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1313" id="d7e1313" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1314" id="d7e1314" shape="rect"><!-- named anchor --></a>17</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1316" id="d7e1316" shape="rect"><!-- named anchor --></a>24</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1318" id="d7e1318" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1320" id="d7e1320" shape="rect"><!-- named anchor --></a>Menopausal
status</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1322" id="d7e1322" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1323" id="d7e1323" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1324" id="d7e1324" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1325" id="d7e1325" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1326" id="d7e1326" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1327" id="d7e1327" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1329" id="d7e1329" shape="rect">
<!-- named anchor --></a>  Premenopausal</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1331" id="d7e1331" shape="rect"><!-- named anchor --></a>28</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1333" id="d7e1333" shape="rect"><!-- named anchor --></a>18.5±16.3</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1335" id="d7e1335" shape="rect"><!-- named anchor --></a>NS</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1337" id="d7e1337" shape="rect"><!-- named anchor --></a>7</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1339" id="d7e1339" shape="rect"><!-- named anchor --></a>21</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1341" id="d7e1341" shape="rect"><!-- named anchor --></a>0.013</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1344" id="d7e1344" shape="rect">
<!-- named anchor --></a>  Postmenopausal</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1346" id="d7e1346" shape="rect"><!-- named anchor --></a>17</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1348" id="d7e1348" shape="rect"><!-- named anchor --></a>27.0±16.2</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1350" id="d7e1350" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1351" id="d7e1351" shape="rect"><!-- named anchor --></a>6</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1353" id="d7e1353" shape="rect"><!-- named anchor --></a>11</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1355" id="d7e1355" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1357" id="d7e1357" shape="rect"><!-- named anchor --></a>Primary tumor size
(cm)</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1359" id="d7e1359" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1360" id="d7e1360" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1361" id="d7e1361" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1362" id="d7e1362" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1363" id="d7e1363" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1364" id="d7e1364" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1366" id="d7e1366" shape="rect"><!-- named anchor --></a>  &lt;2.0</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1368" id="d7e1368" shape="rect"><!-- named anchor --></a>13</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1370" id="d7e1370" shape="rect"><!-- named anchor --></a>16.9±16.6</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1372" id="d7e1372" shape="rect"><!-- named anchor --></a>NS</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1374" id="d7e1374" shape="rect"><!-- named anchor --></a>6</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1376" id="d7e1376" shape="rect"><!-- named anchor --></a>7</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1378" id="d7e1378" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1381" id="d7e1381" shape="rect"><!-- named anchor --></a>  ≥2.0</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1383" id="d7e1383" shape="rect"><!-- named anchor --></a>32</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1385" id="d7e1385" shape="rect"><!-- named anchor --></a>23.7±16.5</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1387" id="d7e1387" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1388" id="d7e1388" shape="rect"><!-- named anchor --></a>20</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1390" id="d7e1390" shape="rect"><!-- named anchor --></a>12</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1392" id="d7e1392" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1394" id="d7e1394" shape="rect"><!-- named anchor --></a>Stage</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1396" id="d7e1396" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1397" id="d7e1397" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1398" id="d7e1398" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1399" id="d7e1399" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1400" id="d7e1400" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1401" id="d7e1401" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1403" id="d7e1403" shape="rect"><!-- named anchor --></a>  II-III</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1405" id="d7e1405" shape="rect"><!-- named anchor --></a>30</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1407" id="d7e1407" shape="rect"><!-- named anchor --></a>18.7±14.4</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1409" id="d7e1409" shape="rect"><!-- named anchor --></a>0.088</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1411" id="d7e1411" shape="rect"><!-- named anchor --></a>10</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1413" id="d7e1413" shape="rect"><!-- named anchor --></a>20</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1415" id="d7e1415" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1419" id="d7e1419" shape="rect"><!-- named anchor --></a>  IV,
recurrent</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1421" id="d7e1421" shape="rect"><!-- named anchor --></a>15</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1423" id="d7e1423" shape="rect"><!-- named anchor --></a>27.7±16.4</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1425" id="d7e1425" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1426" id="d7e1426" shape="rect"><!-- named anchor --></a>8</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1428" id="d7e1428" shape="rect"><!-- named anchor --></a>7</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1430" id="d7e1430" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1432" id="d7e1432" shape="rect"><!-- named anchor --></a>ER</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1434" id="d7e1434" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1435" id="d7e1435" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1436" id="d7e1436" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1437" id="d7e1437" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1438" id="d7e1438" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1439" id="d7e1439" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1441" id="d7e1441" shape="rect"><!-- named anchor --></a>  Positive</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1443" id="d7e1443" shape="rect"><!-- named anchor --></a>19</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1445" id="d7e1445" shape="rect"><!-- named anchor --></a>28.2±17.7</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1447" id="d7e1447" shape="rect"><!-- named anchor --></a>0.024</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1449" id="d7e1449" shape="rect"><!-- named anchor --></a>6</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1451" id="d7e1451" shape="rect"><!-- named anchor --></a>13</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1453" id="d7e1453" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1456" id="d7e1456" shape="rect"><!-- named anchor --></a>  Negative</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1458" id="d7e1458" shape="rect"><!-- named anchor --></a>26</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1460" id="d7e1460" shape="rect"><!-- named anchor --></a>17.0±14.4</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1462" id="d7e1462" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1463" id="d7e1463" shape="rect"><!-- named anchor --></a>12</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1465" id="d7e1465" shape="rect"><!-- named anchor --></a>14</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1467" id="d7e1467" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1469" id="d7e1469" shape="rect"><!-- named anchor --></a>PR</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1471" id="d7e1471" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1472" id="d7e1472" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1473" id="d7e1473" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1474" id="d7e1474" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1475" id="d7e1475" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1476" id="d7e1476" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1478" id="d7e1478" shape="rect"><!-- named anchor --></a>  Positive</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1480" id="d7e1480" shape="rect"><!-- named anchor --></a>15</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1482" id="d7e1482" shape="rect"><!-- named anchor --></a>29.5±17.4</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1484" id="d7e1484" shape="rect"><!-- named anchor --></a>0.026</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1486" id="d7e1486" shape="rect"><!-- named anchor --></a>3</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1488" id="d7e1488" shape="rect"><!-- named anchor --></a>12</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1490" id="d7e1490" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1493" id="d7e1493" shape="rect"><!-- named anchor --></a>  Negative</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1495" id="d7e1495" shape="rect"><!-- named anchor --></a>30</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1497" id="d7e1497" shape="rect"><!-- named anchor --></a>17.9±15.1</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1499" id="d7e1499" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1500" id="d7e1500" shape="rect"><!-- named anchor --></a>15</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1502" id="d7e1502" shape="rect"><!-- named anchor --></a>15</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1504" id="d7e1504" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1506" id="d7e1506" shape="rect"><!-- named anchor --></a>HER-2</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1508" id="d7e1508" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1509" id="d7e1509" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1510" id="d7e1510" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1511" id="d7e1511" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1512" id="d7e1512" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1513" id="d7e1513" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1515" id="d7e1515" shape="rect"><!-- named anchor --></a>  Positive</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1517" id="d7e1517" shape="rect"><!-- named anchor --></a>16</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1519" id="d7e1519" shape="rect"><!-- named anchor --></a>21.6±15.6</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1521" id="d7e1521" shape="rect"><!-- named anchor --></a>NS</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1523" id="d7e1523" shape="rect"><!-- named anchor --></a>9</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1525" id="d7e1525" shape="rect"><!-- named anchor --></a>7</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1527" id="d7e1527" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1530" id="d7e1530" shape="rect"><!-- named anchor --></a>  Negative</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1532" id="d7e1532" shape="rect"><!-- named anchor --></a>29</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1534" id="d7e1534" shape="rect"><!-- named anchor --></a>21.8±17.4</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1536" id="d7e1536" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1537" id="d7e1537" shape="rect"><!-- named anchor --></a>9</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1539" id="d7e1539" shape="rect"><!-- named anchor --></a>20</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1541" id="d7e1541" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1543" id="d7e1543" shape="rect"><!-- named anchor --></a>Triple
negativity</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1545" id="d7e1545" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1546" id="d7e1546" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1547" id="d7e1547" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1548" id="d7e1548" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1549" id="d7e1549" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1550" id="d7e1550" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1553" id="d7e1553" shape="rect"><!-- named anchor --></a>  Yes</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1555" id="d7e1555" shape="rect"><!-- named anchor --></a>15</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1557" id="d7e1557" shape="rect"><!-- named anchor --></a>14.4±11.9</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1559" id="d7e1559" shape="rect"><!-- named anchor --></a>0.041</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1561" id="d7e1561" shape="rect"><!-- named anchor --></a>5</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1563" id="d7e1563" shape="rect"><!-- named anchor --></a>10</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1565" id="d7e1565" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1568" id="d7e1568" shape="rect"><!-- named anchor --></a>  No</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1570" id="d7e1570" shape="rect"><!-- named anchor --></a>30</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1572" id="d7e1572" shape="rect"><!-- named anchor --></a>24.8±17.0</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1574" id="d7e1574" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1575" id="d7e1575" shape="rect"><!-- named anchor --></a>13</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1577" id="d7e1577" shape="rect"><!-- named anchor --></a>17</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1579" id="d7e1579" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1581" id="d7e1581" shape="rect"><!-- named anchor --></a>Tumor grade</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1583" id="d7e1583" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1584" id="d7e1584" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1585" id="d7e1585" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1586" id="d7e1586" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1587" id="d7e1587" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1588" id="d7e1588" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1590" id="d7e1590" shape="rect"><!-- named anchor --></a>  G1</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1592" id="d7e1592" shape="rect"><!-- named anchor --></a>2</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1594" id="d7e1594" shape="rect"><!-- named anchor --></a>2.5±0.1</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1596" id="d7e1596" shape="rect"><!-- named anchor --></a>NS</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1598" id="d7e1598" shape="rect"><!-- named anchor --></a>0</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1600" id="d7e1600" shape="rect"><!-- named anchor --></a>2</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1602" id="d7e1602" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1605" id="d7e1605" shape="rect"><!-- named anchor --></a>  G2</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1607" id="d7e1607" shape="rect"><!-- named anchor --></a>19</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1609" id="d7e1609" shape="rect"><!-- named anchor --></a>21.7±19.1</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1611" id="d7e1611" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1612" id="d7e1612" shape="rect"><!-- named anchor --></a>7</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1614" id="d7e1614" shape="rect"><!-- named anchor --></a>12</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1616" id="d7e1616" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1618" id="d7e1618" shape="rect"><!-- named anchor --></a>  G3</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1620" id="d7e1620" shape="rect"><!-- named anchor --></a>24</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1622" id="d7e1622" shape="rect"><!-- named anchor --></a>23.3±15.4</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1624" id="d7e1624" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1625" id="d7e1625" shape="rect"><!-- named anchor --></a>11</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1627" id="d7e1627" shape="rect"><!-- named anchor --></a>13</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1629" id="d7e1629" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1631" id="d7e1631" shape="rect"><!-- named anchor --></a>Ki-67 (%)</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1633" id="d7e1633" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1634" id="d7e1634" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1635" id="d7e1635" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1636" id="d7e1636" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1637" id="d7e1637" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1638" id="d7e1638" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1640" id="d7e1640" shape="rect"><!-- named anchor --></a>  ≥20</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1642" id="d7e1642" shape="rect"><!-- named anchor --></a>35</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1644" id="d7e1644" shape="rect"><!-- named anchor --></a>22.0±17.5</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1646" id="d7e1646" shape="rect"><!-- named anchor --></a>NS</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1648" id="d7e1648" shape="rect"><!-- named anchor --></a>17</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1650" id="d7e1650" shape="rect"><!-- named anchor --></a>18</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1652" id="d7e1652" shape="rect"><!-- named anchor --></a>0.034</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1655" id="d7e1655" shape="rect"><!-- named anchor --></a>  &lt;20</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1657" id="d7e1657" shape="rect"><!-- named anchor --></a>10</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1659" id="d7e1659" shape="rect"><!-- named anchor --></a>21.6±16.7</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1661" id="d7e1661" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1662" id="d7e1662" shape="rect"><!-- named anchor --></a>1</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1664" id="d7e1664" shape="rect"><!-- named anchor --></a>9</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1666" id="d7e1666" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1668" id="d7e1668" shape="rect"><!-- named anchor --></a>p53 (%)</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1670" id="d7e1670" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1671" id="d7e1671" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1672" id="d7e1672" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1673" id="d7e1673" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1674" id="d7e1674" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1675" id="d7e1675" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1677" id="d7e1677" shape="rect"><!-- named anchor --></a>  ≥10</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1679" id="d7e1679" shape="rect"><!-- named anchor --></a>28</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1681" id="d7e1681" shape="rect"><!-- named anchor --></a>22.9±17.1</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1683" id="d7e1683" shape="rect"><!-- named anchor --></a>NS</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1685" id="d7e1685" shape="rect"><!-- named anchor --></a>10</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1687" id="d7e1687" shape="rect"><!-- named anchor --></a>18</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1689" id="d7e1689" shape="rect"><!-- named anchor --></a>NS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1693" id="d7e1693" shape="rect"><!-- named anchor --></a>  &lt;10</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1695" id="d7e1695" shape="rect"><!-- named anchor --></a>17</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1697" id="d7e1697" shape="rect"><!-- named anchor --></a>19.8±16.1</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1699" id="d7e1699" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1700" id="d7e1700" shape="rect"><!-- named anchor --></a>8</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1702" id="d7e1702" shape="rect"><!-- named anchor --></a>9</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1704" id="d7e1704" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1706" id="d7e1706" shape="rect"><!-- named anchor --></a>Response to
chemotherapy</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1708" id="d7e1708" shape="rect"><!-- named anchor --></a></td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1709" id="d7e1709" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1710" id="d7e1710" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1711" id="d7e1711" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1712" id="d7e1712" shape="rect"><!-- named anchor --></a></td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1713" id="d7e1713" shape="rect"><!-- named anchor --></a></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1715" id="d7e1715" shape="rect"><!-- named anchor --></a>  Responders</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1717" id="d7e1717" shape="rect"><!-- named anchor --></a>32</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1719" id="d7e1719" shape="rect"><!-- named anchor --></a>20.1±11.2</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1721" id="d7e1721" shape="rect"><!-- named anchor --></a>0.042</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1723" id="d7e1723" shape="rect"><!-- named anchor --></a>14</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1725" id="d7e1725" shape="rect"><!-- named anchor --></a>17</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1727" id="d7e1727" shape="rect"><!-- named anchor --></a>0.343</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1730" id="d7e1730" shape="rect">
<!-- named anchor --></a>  Non-responders</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1732" id="d7e1732" shape="rect"><!-- named anchor --></a>13</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1734" id="d7e1734" shape="rect"><!-- named anchor --></a>30.6±8.5</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1736" id="d7e1736" shape="rect"><!-- named anchor --></a></td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1737" id="d7e1737" shape="rect"><!-- named anchor --></a>3</td><td align="right" valign="top" rowspan="1" colspan="1"><a name="d7e1739" id="d7e1739" shape="rect"><!-- named anchor --></a>10</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1741" id="d7e1741" shape="rect"><!-- named anchor --></a></td></tr></tbody></table><div xmlns="http://www.w3.org/1999/xhtml" class="table-wrap-foot">
<div class="footnote"><a name="tfn1-ijo-41-02-0611" id="tfn1-ijo-41-02-0611" shape="rect"><!-- named anchor --></a>
<p id="d7e1744"><span class="generated">[i]</span> ER, estrogen
receptor; PR, progesterone receptor; HER-2, human epidermal growth
factor receptor 2; NS, not statistically significant.</p>
</div>
</div></div></div></div>


<h5>RASSF1A promoter is methylated in breast
cancer cell lines</h5>
<p>Next, we investigated underlying mechanism of
downregulation of <span class="italic">RASSF1A</span>, and tested whether any epigenetic
modification regulates RASSF1A gene expression in breast cancer
cell lines, as reported previously (<a href="#b28-ijo-41-02-0611" class="linksColor">28</a>,<a href="#b29-ijo-41-02-0611" class="linksColor">29</a>).
RASSF1A mRNA and protein levels were restored after treatment with
the demethylating agent in dose-dependent manner, implying that DNA
methylation might be a mechanism involved in the <span class="italic">RASSF1A</span>
inactivation in the selected cells (<a href="#f2-ijo-41-02-0611" class="linksColor">Fig. 2A</a>, upper panel). Moreover,
immunofluorescence study revealed that RASSF1A protein expression
was restored by the demethylating agent, mainly in the perinuclear
area of the cancer cells (<a href="#f2-ijo-41-02-0611" class="linksColor">Fig. 2A</a>,
lower panel). Based on the results of the demethylating agent, the
methylation status of the <span class="italic">RASSF1A</span> promoter was determined by
MSP analysis before and after treatment of 3 different breast
cancer cell lines with 5-aza-deoxycytidine, and the demethylating
agent induced the appearance of unmethylated alleles of the
<span class="italic">RASSF1A</span> (<a href="#f2-ijo-41-02-0611" class="linksColor">Fig. 2B</a>).
Therefore, the decreased <span class="italic">RASSF1A</span> gene expression was
associated with the <span class="italic">RASSF1A</span> promoter methylation in breast
cancer.</p><div id="f2-ijo-41-02-0611"><a class="fancybox" data-fancybox-group="figures" href="/article_images/ijo/41/2/IJO-41-02-0611-g01.jpg" title="Figure 2 - Suppression of RASSF1A by methylation&#xA;in breast cancer. (A) Re-expression of RASSF1A by treatment of 3&#xA;different breast cancer cell lines with 5-azadeoxycytidine. Western&#xA;blot analysis and RT-PCR show that RASSF1A is re-expressed by&#xA;treatment with increasing concentrations of 5-azadeoxycytidine&#xA;(upper panel). β-actin and GAPDH were used as internal controls.&#xA;Immunofluorescence study confirms the re-expression of perinuclear&#xA;RASSF1A (red) in breast cancer cells by 5-azadeoxycytidine&#xA;treatment (x400, lower panel). (B) MSP analysis before and after&#xA;treatment of ZR 75-1, MDA-MB-231 and MCF-7 cells with&#xA;5-azadeoxycytidine. Bisulfite-converted universally methylated&#xA;human DNA standard served as a positive control for methylation,&#xA;and human lymphocyte DNA was included as an unmethylated&#xA;RASSF1A. M, methylated alleles; U, unmethylated alleles."><div class="panel"><table><tbody><tr><td width="115px"><img class="panel-image" src="/article_images/ijo/41/2/IJO-41-02-0611-g01.jpg"></img></td><td><h4>Figure 2</h4><p class="bold">Suppression of RASSF1A by methylation
in breast cancer. (A) Re-expression of RASSF1A by treatment of 3
different breast cancer cell lines with 5-azadeoxycytidine. Western
blot analysis and RT-PCR show that RASSF1A is re-expressed by
treatment with increasing concentrations of 5-azadeoxycytidine
(upper panel). β-actin and GAPDH were used as internal controls.
Immunofluorescence study confirms the re-expression of perinuclear
RASSF1A (red) in breast cancer cells by 5-azadeoxycytidine
treatment (x400, lower panel). (B) MSP analysis before and after
treatment of ZR 75-1, MDA-MB-231 and MCF-7 cells with
5-azadeoxycytidine. Bisulfite-converted universally methylated
human DNA standard served as a positive control for methylation,
and human lymphocyte DNA was included as an unmethylated
RASSF1A. M, methylated alleles; U, unmethylated alleles.</p></td></tr></tbody></table></div></a></div>


<h5>Quantitative analysis of RASSF1A
methylation by pyrosequencing and relationship with
clinicopathological characteristics of breast cancer patients</h5>
<p>The associations between the promoter methylation
status of <span class="italic">RASSF1A</span> and relevant demographic and
clinicopathological characteristics are shown in <a href="#t1-ijo-41-02-0611" class="linksColor">Table I</a>. The 7 CpG sites were analyzed by
methylation-sensitive pyrosequencing and a representative pyrogram
is shown in <a href="#f3-ijo-41-02-0611" class="linksColor">Fig. 3A</a>.
Pyrosequencing showed that the mean level of methylation in 7 CpG
sites in the 45 primary breast cancers ranged from 1.08% to 59.8%,
and 24 of 45 tumors (53.3%) exhibited a high level of methylation
(&gt;20%). Interestingly, triple negative tumors had significantly
lower level of methylation in the promoter region of <span class="italic">RASSF1A</span>
at 14.4±11.9% compared to non-triple negative tumors (24.8±17.0%,
p=0.041; <a href="#f3-ijo-41-02-0611" class="linksColor">Fig. 3B</a>). Furthermore, it
is of an interest to note that the mean level of methylation in
<span class="italic">RASSF1A</span> was significantly higher in patients who did not
respond to docetaxel-based chemotherapy (30.6±8.5 %) than patients
with partial or complete response (20.1±11.2 %, p=0.042; <a href="#f3-ijo-41-02-0611" class="linksColor">Fig. 3C</a>). Mean level of methylation in 7
CpG sites of the promoter region of <span class="italic">RASSF1A</span> in ER-positive
tumors was significantly higher at 28.2±17.7% compared to
ER-negative tumors (17.0±14.4%, p=0.024). Positive for PR showed
the same pattern of association as observed in ER (positive:
29.5±17.4%, negative: 17.9±15.1%, p=0.026). However, there was no
significant correlation between RASSF1A protein expression and the
level of promoter methylation or any clinicopathological
characterisitics in primary breast cancers in this study (<a href="#t1-ijo-41-02-0611" class="linksColor">Table I</a>).</p><div id="f3-ijo-41-02-0611"><a class="fancybox" data-fancybox-group="figures" href="/article_images/ijo/41/2/IJO-41-02-0611-g02.jpg" title="Figure 3 - Quantitative analysis of&#xA;RASSF1A methylation by pyrosequencing. (A) Pyrogram from&#xA;quantification of methylation of 7 CpG sites at the RASSF1A&#xA;promoter. During the pyrosequencing reaction, a ‘C’ is incorporated&#xA;if the template CpG is methylated, while a ‘T’ is incorporated if&#xA;the template CpG is unmethylated. In the resulting pyrogram, the&#xA;proportion of C:T reflects the degree of methylation at the&#xA;particular CpG sites assessed. (B) Comparison of mean level of&#xA;methylation of RASSF1A between non-triple negative breast cancer&#xA;(TNBC) and TNBC patients. Bar indicates mean level of methylation&#xA;of RASSF1A in each group. P denotes significance of t-test. (C)&#xA;Comparison of mean level of methylation of RASSF1A between&#xA;non-responder and responder to chemotherapy. Bar indicates mean&#xA;level of methylation of RASSF1A in each group."><div class="panel"><table><tbody><tr><td width="115px"><img class="panel-image" src="/article_images/ijo/41/2/IJO-41-02-0611-g02.jpg"></img></td><td><h4>Figure 3</h4><p class="bold">Quantitative analysis of
RASSF1A methylation by pyrosequencing. (A) Pyrogram from
quantification of methylation of 7 CpG sites at the RASSF1A
promoter. During the pyrosequencing reaction, a ‘C’ is incorporated
if the template CpG is methylated, while a ‘T’ is incorporated if
the template CpG is unmethylated. In the resulting pyrogram, the
proportion of C:T reflects the degree of methylation at the
particular CpG sites assessed. (B) Comparison of mean level of
methylation of RASSF1A between non-triple negative breast cancer
(TNBC) and TNBC patients. Bar indicates mean level of methylation
of RASSF1A in each group. P denotes significance of t-test. (C)
Comparison of mean level of methylation of RASSF1A between
non-responder and responder to chemotherapy. Bar indicates mean
level of methylation of RASSF1A in each group.</p></td></tr></tbody></table></div></a></div>
<p>Multivariate analysis showed that low level of
methylation (&lt;20%) in <span class="italic">RASSF1A</span> was an independent
predictor for response to chemotherapy after adjusted for ER
(negative vs positive), PR (negative vs positive), HER-2 (negative
vs positive), tumor grade (grade I/II vs III), p53 immunostaining
(low; &lt;20% vs high; ≥20%), and Ki-67 (low vs high) in these 45
patients (odds ratio = 15.99, 95% confidence interval =
1.16–219.29, p=0.03; <a href="#t2-ijo-41-02-0611" class="linksColor">Table II</a>).
Patients with low level of p53 immunostaining (&lt;20%) were also
more sensitive to docetaxel-based chemotherapy than the patients
with tumors of high level of p53 immunostaining.</p><div class="panel" id="t2-ijo-41-02-0611"><a href="#tb_t2-ijo-41-02-0611" class="fancybox" data-fancybox-group="tables" title="Table II - Multivariate logistic regression&#xA;model for response to chemotherapy."><table><tbody><tr><td width="115px"><img class="panel-image" src="/images/table-icon.jpg"></img></td><td><h4>Table II</h4><p><b>Multivariate logistic regression
model for response to chemotherapy.</b></p></td></tr></tbody></table></a><div style="display:none;"><div id="tb_t2-ijo-41-02-0611"><h4>Table II</h4><p><b>Multivariate logistic regression
model for response to chemotherapy.</b></p><table xmlns="http://www.w3.org/1999/xhtml" frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1755" id="d7e1755" shape="rect"><!-- named anchor --></a>Factor</th><th colspan="2" align="center" valign="top" rowspan="1"><a name="d7e1757" id="d7e1757" shape="rect"><!-- named anchor --></a>Response to
chemotherapy
<hr /></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1761" id="d7e1761" shape="rect"><!-- named anchor --></a></th><th align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1762" id="d7e1762" shape="rect"><!-- named anchor --></a>OR (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1764" id="d7e1764" shape="rect"><!-- named anchor --></a>P</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1768" id="d7e1768" shape="rect"><!-- named anchor --></a>ER (negative vs
positive)</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1770" id="d7e1770" shape="rect"><!-- named anchor --></a>0.00</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1772" id="d7e1772" shape="rect"><!-- named anchor --></a>0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1775" id="d7e1775" shape="rect"><!-- named anchor --></a>PR (negative vs
positive)</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1777" id="d7e1777" shape="rect"><!-- named anchor --></a>8.970E8</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1779" id="d7e1779" shape="rect"><!-- named anchor --></a>0.99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1782" id="d7e1782" shape="rect"><!-- named anchor --></a>HER-2 (negative vs
positive)</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1784" id="d7e1784" shape="rect"><!-- named anchor --></a>4.31
(.53–34.96)</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1786" id="d7e1786" shape="rect"><!-- named anchor --></a>0.17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1789" id="d7e1789" shape="rect"><!-- named anchor --></a>Grade (I vs
II/III)</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1791" id="d7e1791" shape="rect"><!-- named anchor --></a>0.61
(.016–23.35)</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1793" id="d7e1793" shape="rect"><!-- named anchor --></a>0.79</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1796" id="d7e1796" shape="rect"><!-- named anchor --></a>p53
immunoreactivity (low vs high)</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1798" id="d7e1798" shape="rect"><!-- named anchor --></a>49.02
(1.46–1639.25)</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1800" id="d7e1800" shape="rect"><!-- named anchor --></a>0.03</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1803" id="d7e1803" shape="rect"><!-- named anchor --></a>Ki-67
immunoreactivity (low vs high)</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1805" id="d7e1805" shape="rect"><!-- named anchor --></a>0.17
(.004–7.06)</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1807" id="d7e1807" shape="rect"><!-- named anchor --></a>0.35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1810" id="d7e1810" shape="rect"><!-- named anchor --></a><i>RASSF1A</i>
methylation (low vs high)</td><td align="left" valign="top" rowspan="1" colspan="1"><a name="d7e1814" id="d7e1814" shape="rect"><!-- named anchor --></a>15.99
(1.16–219.29)</td><td align="center" valign="top" rowspan="1" colspan="1"><a name="d7e1816" id="d7e1816" shape="rect"><!-- named anchor --></a>0.03</td></tr></tbody></table><div xmlns="http://www.w3.org/1999/xhtml" class="table-wrap-foot">
<div class="footnote"><a name="tfn2-ijo-41-02-0611" id="tfn2-ijo-41-02-0611" shape="rect"><!-- named anchor --></a>
<p id="d7e1820"><span class="generated">[i]</span> OR, odds ratio;
CI, confidence interval; ER, estrogen receptor; PR, progesterone
receptor; HER-2, human epidermal growth factor receptor 2.</p>
</div>
</div></div></div></div>


<h5>RASSF1A modulates docetaxel-induced cell
death</h5>
<p>Since the docetaxel-based chemotherapy seemed less
effective in patients with methylated promoter region of
<span class="italic">RASSF1A</span>, we examined potential interaction between
<span class="italic">RASSF1A</span> and docetaxel. Therefore, we transfected
<span class="italic">RASSF1A</span> or control vector to the breast cancer cells
(ZR-75-1, MDA-MB-231, MCF-7), and investigated whether
reintroduction of <span class="italic">RASSF1A</span> had any growth inhibitory effect
on breast cancer cells. As shown in <a href="#f4-ijo-41-02-0611" class="linksColor">Fig. 4A</a>, the number of round-shape cells
which are typical features of apoptotic cells was increased in
<span class="italic">RASSF1A</span> transfected cells compared with the control
vector-transfected cells and the effect was greatly enhanced after
treatment of docetaxel. Next, the cooperative effect was confirmed
in a proliferation assay showing that docetaxel induced a marked
reduction of [<span class="superscript">3</span>H]-thymidine incorporation in the cells
stably transfected with <span class="italic">RASSF1A</span>, compared with the control
vector-transfected cells (<a href="#f4-ijo-41-02-0611" class="linksColor">Fig.
4B</a>). Therefore, these results indicate that the
anti-proliferative effect of docetaxel was enhanced in the presence
of <span class="italic">RASSF1A</span> in breast cancer cells.</p><div id="f4-ijo-41-02-0611"><a class="fancybox" data-fancybox-group="figures" href="/article_images/ijo/41/2/IJO-41-02-0611-g03.jpg" title="Figure 4 - RASSF1A modulates growth inhibitory&#xA;effect of docetaxel. (A) The effect of RASSF1A on docetaxel-induced&#xA;cell growth inhibition in 3 breast cancer cell lines was analyzed&#xA;by phase contrast light microscopy. Control vector indicates&#xA;pcDNA3.1. (B) Upper right panel, expression status of RASSF1A in&#xA;RASSF1A and control vector stably transfected cells. Upper left and&#xA;low panel, [3H]-thymidine incorporation assay in each&#xA;stably transfected breast cancer cell line. Statistical analysis&#xA;was performed on the basis of PBS-treated, control vector&#xA;transfected cells in each cell type. *p&lt;0.05."><div class="panel"><table><tbody><tr><td width="115px"><img class="panel-image" src="/article_images/ijo/41/2/IJO-41-02-0611-g03.jpg"></img></td><td><h4>Figure 4</h4><p class="bold">RASSF1A modulates growth inhibitory
effect of docetaxel. (A) The effect of RASSF1A on docetaxel-induced
cell growth inhibition in 3 breast cancer cell lines was analyzed
by phase contrast light microscopy. Control vector indicates
pcDNA3.1. (B) Upper right panel, expression status of RASSF1A in
RASSF1A and control vector stably transfected cells. Upper left and
low panel, [3H]-thymidine incorporation assay in each
stably transfected breast cancer cell line. Statistical analysis
was performed on the basis of PBS-treated, control vector
transfected cells in each cell type. *p&lt;0.05.</p></td></tr></tbody></table></div></a></div>


<h5>RASSF1A enhances docetaxel-induced cell
cycle arrest</h5>
<p>The cooperative effects of <span class="italic">RASSF1A</span> and
docetaxel in the cell survival and proliferation prompted us to
investigate whether reintroduction of <span class="italic">RASSF1A</span>, in addition
to docetaxel, has any impact on the cell cycle progression. When
the <span class="italic">RASSF1A</span>-transfected breast cancer cells were treated
with docetaxel for 24 h, they showed statistically significant
increase of G2/M phase cell population, compared to those of empty
vector transfected cells (p=0.02, <a href="#f5-ijo-41-02-0611" class="linksColor">Fig.
5A</a>). The result indicates that the cooperative effect of
<span class="italic">RASSF1A</span> and docetaxel is accompanied with cell cycle arrest
at the G2/M phase. Further analysis using western blot analysis
showed that the cell cycle arrest at the G2/M phase in the breast
cancer cells was associated with the induction of cyclin B1, Cdk2
and p21 by both RASSF1A and docetaxel (<a href="#f5-ijo-41-02-0611" class="linksColor">Fig. 5B</a>). Maximum cyclin B1, Cdk2 and p21
induction was observed when docetaxel was applied to the
<span class="italic">RASSF1A</span>-transfected breast cancer cells, whereas Cdk1, Cdk4,
and cyclin D1 were greatly decreased when breast cancer cells
reintroduced with <span class="italic">RASSF1A</span> were treated with docetaxel. These
findings indicate that the effects of <span class="italic">RASSF1A</span> and docetaxel
on the G2/M phase cell cycle arrest are associated with
accumulation of cyclin B1/Cdk2/p21 and suppression of Cdk1, Cdk4,
and cyclin D1 in breast cancer cells.</p><div id="f5-ijo-41-02-0611"><a class="fancybox" data-fancybox-group="figures" href="/article_images/ijo/41/2/IJO-41-02-0611-g04.jpg" title="Figure 5 - RASSF1A enhances docetaxel-induced&#xA;cell cycle arrest. (A) The effect of RASSF1A on docetaxel-induced&#xA;cell cycle arrest was evaluated in MDA-MB-231 cells stably&#xA;transfected with RASSF1A or control vector. Cells were&#xA;analyzed for cell cycle progression. Positions of cell populations&#xA;with 2N and 4N DNA content are indicated (upper panel). Histogram&#xA;plotting of the cell cycle progression is shown in lower left,&#xA;while comparison of cells in G2/M phase is shown in lower right.&#xA;Columns, means (n=3); bars, SEM; *p&lt;0.05. Expression&#xA;of cell cycle regulating proteins is shown by western blot&#xA;analysis. Three breast cancer cell lines transfected with RASSF1A&#xA;and control vector were analyzed with or without exposure to&#xA;docetaxel (10 nM)."><div class="panel"><table><tbody><tr><td width="115px"><img class="panel-image" src="/article_images/ijo/41/2/IJO-41-02-0611-g04.jpg"></img></td><td><h4>Figure 5</h4><p class="bold">RASSF1A enhances docetaxel-induced
cell cycle arrest. (A) The effect of RASSF1A on docetaxel-induced
cell cycle arrest was evaluated in MDA-MB-231 cells stably
transfected with RASSF1A or control vector. Cells were
analyzed for cell cycle progression. Positions of cell populations
with 2N and 4N DNA content are indicated (upper panel). Histogram
plotting of the cell cycle progression is shown in lower left,
while comparison of cells in G2/M phase is shown in lower right.
Columns, means (n=3); bars, SEM; *p&lt;0.05. Expression
of cell cycle regulating proteins is shown by western blot
analysis. Three breast cancer cell lines transfected with RASSF1A
and control vector were analyzed with or without exposure to
docetaxel (10 nM).</p></td></tr></tbody></table></div></a></div>



<h4>Discussion</h4>
<p><span class="italic">RASSF1A</span> has been reported to be frequently
silenced in many cancer types including breast cancer; however, the
biologic relevance in clinical standpoint has not yet been clearly
characterized. Because there is a probability that unsatisfactory
response in breast cancer treatment may in part be due to silencing
of gene, the role and clinical relevance of a frequently silenced
tumor suppressor gene, <span class="italic">RASSF1A</span>, was examined in this study.
In the current study, we found that the promoter region of
<span class="italic">RASSF1A</span> was frequently methylated in the primary breast
cancer samples from 45 locally advanced or metastatic cancer
patients, in good agreement with previous reports. In addition, we
showed that level of methylation of <span class="italic">RASSF1A</span> was independent
factor for response to docetaxel-based chemotherapy in this study.
Moreover, RASSF1A enhanced docetaxel-mediated growth inhibition by
inducing cell cycle arrest and altering the level of related
proteins. Our results demonstrated that methylation status of
<span class="italic">RASSF1A</span> modulates the efficacy of docetaxel chemotherapy and
regulates docetaxel mediated cell cycle arrest in breast
cancers.</p>
<p>There are a few studies suggesting the methylated
<span class="italic">RASSF1A</span> as a potential biomarker for poor prognosis in
breast cancer (<a href="#b12-ijo-41-02-0611" class="linksColor">12</a>–<a href="#b14-ijo-41-02-0611" class="linksColor">14</a>). However, no biologically relevant
mechanism, thus far, has been presented. In this context, we showed
herein that the methylation status of <span class="italic">RASSF1A</span> was
significantly associated with response to docetaxel-based
chemotherapy: cell line studies showed that <span class="italic">RASSF1A per se</span>
had docetaxel-like effect in suppressing growth and proliferation
of breast cancer cells via inducing cell cycle arrest. Furthermore,
cooperative activity of <span class="italic">RASSF1A</span> in docetaxel-induced cell
cycle arrest could be a potential mechanism for differential
response among breast cancer patients.</p>
<p>Docetaxel is one of the prototype taxane and a front
line chemotherapeutic agent in the treatment of breast, ovary,
lung, and head and neck cancers. Despite of its widespread use and
success in clinical practice, there are significant shortcomings
including myelosuppression, peripheral neuropathy, and primary or
secondary resistance (<a href="#b30-ijo-41-02-0611" class="linksColor">30</a>).
Nevertheless, there is no rational biomarker for the identification
of patients who are most likely to respond to docetaxel. Of the
predictive markers for the response to neoadjuvant chemotherapy,
biology-based tumor types have been shown to be most consistent and
reproducible among the studies (<a href="#b4-ijo-41-02-0611" class="linksColor">4</a>). However, it is still unsatisfactory
marker due to strong heterogeneity within the subgroups. More
mechanistic markers such as Ki-67 (<a href="#b31-ijo-41-02-0611" class="linksColor">31</a>) and topoisomerase IIα (<a href="#b32-ijo-41-02-0611" class="linksColor">32</a>) have also been suggested as valuable
predictive markers for response to anthracyclines and other
chemotherapeutics. For the taxanes, however, no biologic marker has
been suggested for the prediction of response based on mechanistic
study. In the present study, we found a significant association
between the methylation level of <span class="italic">RASSF1A</span> and response to
docetaxel-based chemotherapy in patients with locally advanced or
recurrent breast cancer. Additional multivariate analysis showed
that low level of methylation (&lt;20%) in the promoter region of
<span class="italic">RASSF1A</span> was an independent factor for response to
docetaxel-based chemotherapy after adjusted for ER, PR, HER-2, p53
immunoreactivity, and Ki-67 staining. Furthermore, the specific
modulating effect of <span class="italic">RASSF1A</span> on docetaxel-induced
cytotoxicity was demonstrated in the cell culture system.
Therefore, the loss of <span class="italic">RASSF1A</span> for the prediction of
docetaxel-based chemo-therapy also seems to deserve further
investigation.</p>
<p>It is now well known that taxanes exert their
anti-cancer effect by inducing mitotic arrest of cancer cells. When
cells are exposed to anti-mitotics, they are arrested in mitosis
and then undergo one of several fates; death in mitosis, unequal
division, or exit without division (<a href="#b33-ijo-41-02-0611" class="linksColor">33</a>). However, little is known about how
cells respond to this prolonged cell cycle delay. Recent studies
suggested that commitment to mitotic exit is determined by the
level of cyclin B1 in anti-mitotics exposed cells (<a href="#b34-ijo-41-02-0611" class="linksColor">34</a>). Therefore, it seems important to
define the factors that govern the degradation of cyclin B1 during
a prolonged mitotic arrest. Notably, our present results showed
that overexpression of <span class="italic">RASSF1A</span> in breast cancers induced the
accumulation of cyclin B1, as observed in docetaxel-treated cells
in consistent with previous studies (<a href="#b21-ijo-41-02-0611" class="linksColor">21</a>,<a href="#b35-ijo-41-02-0611" class="linksColor">35</a>).
Furthermore, the accumulation of cyclin B1 in the
<span class="italic">RASSF1A</span>-transfected cells was significantly enhanced by
docetaxel. Thus, <span class="italic">RASSF1A</span> could be considered as one of the
factors controlling degradation of cyclin B1 during the mitotic
arrest which was induced by docetaxel in breast cancer cells. In
the present study, the accumulation of p21 and decreased levels of
Cdk 1, Cdk 4, and cyclin D1 were also found to be involved in the
induction of cell cycle arrest and apoptosis by both docetaxel and
<span class="italic">RASSF1A</span>. In addition, decreased expression of Cdk 1 by
RASSF1A might also contribute to cell death after mitotic exit,
since Cdk 1 has been shown to inhibit caspase-9 (<a href="#b36-ijo-41-02-0611" class="linksColor">36</a>). Our present observations therefore
show that RASSF1A might be an important biologic contributor to
docetaxel-induced cell cycle arrest and, finally, cell death in
breast cancer cells.</p>
<p>In conclusion, the data presented herein led us to
propose that hypermethylated <span class="italic">RASSF1A</span> might be an important
modulating factor for efficacy of docetaxel-based chemotherapy in
breast cancers. We also provided mechanistic data that the tumor
suppressor, <span class="italic">RASSF1A</span>, has a cooperative effect along with
docetaxel in inducing cell cycle arrest in breast cancer. Our
results are expected to contribute to the identification of
biomarkers in predicting the response of breast cancer patients to
docetaxel. Since our data are limited by the small sample size and
locally advanced stage cancers in most of the cases, the
statistical significances shown here are still marginal. Therefore,
further research with a large number of clinical samples is needed
to confirm our results.</p>



<a class="linksColor">
</a>
<h4>Acknowledgements</h4>
<p>This study was supported by a grant of
the Korea Healthcare technology R&amp;D Project, Ministry for
Health, Welfare &amp; Family Affairs, Republic of Korea (A084400).
Tissue samples were provided by the Korean Lung Tissue Bank through
the Infrastructure Project for Basic Science of the Ministry of
Education, Science and Technology, Korea.</p>

<a class="linksColor">
</a>
<a class="linksColor">
</a>
<h4>References</h4>
<table xmlns="http://www.w3.org/1999/xhtml" class="ref-list"><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">1</span> <a name="b1-ijo-41-02-0611" id="b1-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e759" id="d7e759" shape="rect">
<!-- named anchor --></a>Jung KW, Park S, Kong HJ, et al: Cancer
statistics in Korea: incidence, mortality, survival, and prevalence
in 2008. Cancer Res Treat. 43:1–11. 2011. <a target="xrefwindow" href="http://dx.doi.org/10.4143/crt.2011.43.1.1" id="d7e761" name="d7e761" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Cancer%20statistics%20in%20Korea:%20incidence,%20mortality,%20survival,%20and%20prevalence%20in%202008" id="d7e764" name="d7e764" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/21509157" id="d7e767" name="d7e767" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">2</span> <a name="b2-ijo-41-02-0611" id="b2-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e772" id="d7e772" shape="rect">
<!-- named anchor --></a>Rastogi P, Anderson SJ, Bear HD, et al:
Preoperative chemotherapy: updates of National Surgical Adjuvant
Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol.
26:778–785. 2008. <a target="xrefwindow" href="http://dx.doi.org/10.1200/JCO.2007.15.0235" id="d7e774" name="d7e774" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Preoperative%20chemotherapy:%20updates%20of%20National%20Surgical%20Adjuvant%20Breast%20and%20Bowel%20Project%20Protocols%20B-18%20and%20B-27" id="d7e777" name="d7e777" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/18258986" id="d7e780" name="d7e780" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">3</span> <a name="b3-ijo-41-02-0611" id="b3-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e785" id="d7e785" shape="rect">
<!-- named anchor --></a>Mauri D, Pavlidis N and Ioannidis JP:
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a
meta-analysis. J Natl Cancer Inst. 97:188–194. 2005. <a target="xrefwindow" href="http://dx.doi.org/10.1093/jnci/dji021" id="d7e787" name="d7e787" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Neoadjuvant%20versus%20adjuvant%20systemic%20treatment%20in%20breast%20cancer:%20a%20meta-analysis" id="d7e790" name="d7e790" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/15687361" id="d7e793" name="d7e793" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">4</span> <a name="b4-ijo-41-02-0611" id="b4-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e798" id="d7e798" shape="rect">
<!-- named anchor --></a>Darb-Esfahani S, Loibl S, Muller BM, et
al: Identification of biology-based breast cancer types with
distinct predictive and prognostic features: role of steroid
hormone and HER2 receptor expression in patients treated with
neoadjuvant anthracycline/taxane-based chemotherapy. Breast Cancer
Res. 11:R692009. <a target="xrefwindow" href="http://dx.doi.org/10.1186/bcr2363" id="d7e800" name="d7e800" shape="rect">View
Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Identification%20of%20biology-based%20breast%20cancer%20types%20with%20distinct%20predictive%20and%20prognostic%20features:%20role%20of%20steroid%20hormone%20and%20HER2%20receptor%20expression%20in%20patients%20treated%20with%20neoadjuvant%20anthracycline/taxane-based%20chemotherapy" id="d7e803" name="d7e803" shape="rect">Google Scholar</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">5</span> <a name="b5-ijo-41-02-0611" id="b5-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e808" id="d7e808" shape="rect">
<!-- named anchor --></a>Chang HR, Glaspy J, Allison MA, et al:
Differential response of triple-negative breast cancer to a
docetaxel and carboplatin-based neoadjuvant treatment. Cancer.
116:4227–4237. 2010. <a target="xrefwindow" href="http://dx.doi.org/10.1002/cncr.25309" id="d7e810" name="d7e810" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Differential%20response%20of%20triple-negative%20breast%20cancer%20to%20a%20docetaxel%20and%20carboplatin-based%20neoadjuvant%20treatment" id="d7e813" name="d7e813" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/20549829" id="d7e816" name="d7e816" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">6</span> <a name="b6-ijo-41-02-0611" id="b6-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e821" id="d7e821" shape="rect">
<!-- named anchor --></a>Christensen BC, Kelsey KT, Zheng S, et al:
Breast cancer DNA methylation profiles are associated with tumor
size and alcohol and folate intake. PLoS Genet. 6:e10010432010.
<a target="xrefwindow" href="http://dx.doi.org/10.1371/journal.pgen.1001043" id="d7e823" name="d7e823" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Breast%20cancer%20DNA%20methylation%20profiles%20are%20associated%20with%20tumor%20size%20and%20alcohol%20and%20folate%20intake" id="d7e826" name="d7e826" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/20686660" id="d7e829" name="d7e829" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">7</span> <a name="b7-ijo-41-02-0611" id="b7-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e834" id="d7e834" shape="rect">
<!-- named anchor --></a>Yan PS, Shi H, Rahmatpanah F, et al:
Differential distribution of DNA methylation within the RASSF1A CpG
island in breast cancer. Cancer Res. 63:6178–6186. 2003.<a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/14559801" id="d7e836" name="d7e836" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">8</span> <a name="b8-ijo-41-02-0611" id="b8-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e841" id="d7e841" shape="rect">
<!-- named anchor --></a>Yeo W, Wong WL, Wong N, Law BK, Tse GM and
Zhong S: High frequency of promoter hypermethylation of RASSF1A in
tumorous and non-tumourous tissue of breast cancer. Pathology.
37:125–130. 2005. <a target="xrefwindow" href="http://dx.doi.org/10.1080/00313020500058623" id="d7e843" name="d7e843" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=High%20frequency%20of%20promoter%20hypermethylation%20of%20RASSF1A%20in%20tumorous%20and%20non-tumourous%20tissue%20of%20breast%20cancer" id="d7e846" name="d7e846" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/16028839" id="d7e849" name="d7e849" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">9</span> <a name="b9-ijo-41-02-0611" id="b9-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e854" id="d7e854" shape="rect">
<!-- named anchor --></a>Honorio S, Agathanggelou A, Schuermann M,
et al: Detection of RASSF1A aberrant promoter hypermethylation in
sputum from chronic smokers and ductal carcinoma in situ from
breast cancer patients. Oncogene. 22:147–150. 2003. <a target="xrefwindow" href="http://dx.doi.org/10.1038/sj.onc.1206057" id="d7e856" name="d7e856" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Detection%20of%20RASSF1A%20aberrant%20promoter%20hypermethylation%20in%20sputum%20from%20chronic%20smokers%20and%20ductal%20carcinoma%20in%20situ%20from%20breast%20cancer%20patients" id="d7e859" name="d7e859" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/12527916" id="d7e862" name="d7e862" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">10</span> <a name="b10-ijo-41-02-0611" id="b10-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e867" id="d7e867" shape="rect">
<!-- named anchor --></a>Shukla S, Mirza S, Sharma G, Parshad R,
Gupta SD and Ralhan R: Detection of RASSF1A and RARbeta
hypermethylation in serum DNA from breast cancer patients.
Epigenetics. 1:88–93. 2006. <a target="xrefwindow" href="http://dx.doi.org/10.4161/epi.1.2.2679" id="d7e869" name="d7e869" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Detection%20of%20RASSF1A%20and%20RARbeta%20hypermethylation%20in%20serum%20DNA%20from%20breast%20cancer%20patients" id="d7e872" name="d7e872" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/17998817" id="d7e875" name="d7e875" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">11</span> <a name="b11-ijo-41-02-0611" id="b11-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e881" id="d7e881" shape="rect">
<!-- named anchor --></a>Yazici H, Terry MB, Cho YH, et al:
Aberrant methylation of RASSF1A in plasma DNA before breast cancer
diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol
Biomarkers Prev. 18:2723–2725. 2009. <a target="xrefwindow" href="http://dx.doi.org/10.1158/1055-9965.EPI-08-1237" id="d7e883" name="d7e883" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Aberrant%20methylation%20of%20RASSF1A%20in%20plasma%20DNA%20before%20breast%20cancer%20diagnosis%20in%20the%20Breast%20Cancer%20Family%20Registry" id="d7e886" name="d7e886" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/19755643" id="d7e889" name="d7e889" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">12</span> <a name="b12-ijo-41-02-0611" id="b12-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e894" id="d7e894" shape="rect">
<!-- named anchor --></a>Kioulafa M, Kaklamanis L, Mavroudis D,
Georgoulias V and Lianidou ES: Prognostic significance of RASSF1A
promoter methylation in operable breast cancer. Clin Biochem.
42:970–975. 2009. <a target="xrefwindow" href="http://dx.doi.org/10.1016/j.clinbiochem.2009.04.003" id="d7e896" name="d7e896" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Prognostic%20significance%20of%20RASSF1A%20promoter%20methylation%20in%20operable%20breast%20cancer" id="d7e899" name="d7e899" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/19374895" id="d7e902" name="d7e902" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">13</span> <a name="b13-ijo-41-02-0611" id="b13-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e907" id="d7e907" shape="rect">
<!-- named anchor --></a>Karray-Chouayekh S, Trifa F, Khabir A, et
al: Aberrant methylation of RASSF1A is associated with poor
survival in Tunisian breast cancer patients. J Cancer Res Clin
Oncol. 136:203–210. 2010. <a target="xrefwindow" href="http://dx.doi.org/10.1007/s00432-009-0649-6" id="d7e909" name="d7e909" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Aberrant%20methylation%20of%20RASSF1A%20is%20associated%20with%20poor%20survival%20in%20Tunisian%20breast%20cancer%20patients" id="d7e912" name="d7e912" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/19657672" id="d7e915" name="d7e915" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">14</span> <a name="b14-ijo-41-02-0611" id="b14-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e920" id="d7e920" shape="rect">
<!-- named anchor --></a>Martins AT, Monteiro P, Ramalho-Carvalho
J, et al: High RASSF1A promoter methylation levels are predictive
of poor prognosis in fine-needle aspirate washings of breast cancer
lesions. Breast Cancer Res Treat. 129:1–9. 2011. <a target="xrefwindow" href="http://dx.doi.org/10.1007/s10549-010-1160-0" id="d7e922" name="d7e922" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=High%20RASSF1A%20promoter%20methylation%20levels%20are%20predictive%20of%20poor%20prognosis%20in%20fine-needle%20aspirate%20washings%20of%20breast%20cancer%20lesions" id="d7e925" name="d7e925" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/20842524" id="d7e928" name="d7e928" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">15</span> <a name="b15-ijo-41-02-0611" id="b15-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e933" id="d7e933" shape="rect">
<!-- named anchor --></a>Kim DH, Kim JS, Ji YI, et al:
Hypermethylation of RASSF1A promoter is associated with the age at
starting smoking and a poor prognosis in primary non-small cell
lung cancer. Cancer Res. 63:3743–3746. 2003.<a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/12839968" id="d7e935" name="d7e935" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">16</span> <a name="b16-ijo-41-02-0611" id="b16-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e940" id="d7e940" shape="rect">
<!-- named anchor --></a>Wang J, Lee JJ, Wang L, et al: Value of
p16INK4a and RASSF1A promoter hypermethylation in prognosis of
patients with resectable non-small cell lung cancer. Clin Cancer
Res. 10:6119–6125. 2004. <a target="xrefwindow" href="http://dx.doi.org/10.1158/1078-0432.CCR-04-0652" id="d7e942" name="d7e942" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Value%20of%20p16INK4a%20and%20RASSF1A%20promoter%20hypermethylation%20in%20prognosis%20of%20patients%20with%20resectable%20non-small%20cell%20lung%20cancer" id="d7e945" name="d7e945" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/15447998" id="d7e948" name="d7e948" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">17</span> <a name="b17-ijo-41-02-0611" id="b17-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e953" id="d7e953" shape="rect">
<!-- named anchor --></a>Seidel C, Bartel F, Rastetter M, et al:
Alterations of cancer-related genes in soft tissue sarcomas:
hypermethylation of RASSF1A is frequently detected in
leiomyosarcoma and associated with poor prognosis in sarcoma. Int J
Cancer. 114:442–447. 2005. <a target="xrefwindow" href="http://dx.doi.org/10.1002/ijc.20707" id="d7e955" name="d7e955" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Alterations%20of%20cancer-related%20genes%20in%20soft%20tissue%20sarcomas:%20hypermethylation%20of%20RASSF1A%20is%20frequently%20detected%20in%20leiomyosarcoma%20and%20associated%20with%20poor%20prognosis%20in%20sarcoma" id="d7e958" name="d7e958" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/15551306" id="d7e961" name="d7e961" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">18</span> <a name="b18-ijo-41-02-0611" id="b18-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e966" id="d7e966" shape="rect">
<!-- named anchor --></a>Fischer JR, Ohnmacht U, Rieger N, et al:
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor
prognosis of patients with malignant mesothelioma. Lung Cancer.
54:109–116. 2006. <a target="xrefwindow" href="http://dx.doi.org/10.1016/j.lungcan.2006.06.017" id="d7e968" name="d7e968" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Promoter%20methylation%20of%20RASSF1A,%20RARbeta%20and%20DAPK%20predict%20poor%20prognosis%20of%20patients%20with%20malignant%20mesothelioma" id="d7e971" name="d7e971" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/16893590" id="d7e974" name="d7e974" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">19</span> <a name="b19-ijo-41-02-0611" id="b19-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e979" id="d7e979" shape="rect">
<!-- named anchor --></a>Ahmed-Choudhury J, Agathanggelou A, Fenton
SL, et al: Transcriptional regulation of cyclin A2 by RASSF1A
through the enhanced binding of p120E4F to the cyclin A2 promoter.
Cancer Res. 65:2690–2697. 2005. <a target="xrefwindow" href="http://dx.doi.org/10.1158/0008-5472.CAN-04-3593" id="d7e981" name="d7e981" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Transcriptional%20regulation%20of%20cyclin%20A2%20by%20RASSF1A%20through%20the%20enhanced%20binding%20of%20p120E4F%20to%20the%20cyclin%20A2%20promoter" id="d7e984" name="d7e984" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/15805267" id="d7e987" name="d7e987" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">20</span> <a name="b20-ijo-41-02-0611" id="b20-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e992" id="d7e992" shape="rect">
<!-- named anchor --></a>Donninger H, Vos MD and Clark GJ: The
RASSF1A tumor suppressor. J Cell Sci. 120:3163–3172. 2007.
<a target="xrefwindow" href="http://dx.doi.org/10.1242/jcs.010389" id="d7e994" name="d7e994" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=The%20RASSF1A%20tumor%20suppressor" id="d7e997" name="d7e997" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/17878233" id="d7e1000" name="d7e1000" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">21</span> <a name="b21-ijo-41-02-0611" id="b21-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1005" id="d7e1005" shape="rect">
<!-- named anchor --></a>Song MS, Song SJ, Ayad NG, et al: The
tumour suppressor RASSF1A regulates mitosis by inhibiting the
APC-Cdc20 complex. Nat Cell Biol. 6:129–137. 2004. <a target="xrefwindow" href="http://dx.doi.org/10.1038/ncb1091" id="d7e1007" name="d7e1007" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=The%20tumour%20suppressor%20RASSF1A%20regulates%20mitosis%20by%20inhibiting%20the%20APC-Cdc20%20complex" id="d7e1010" name="d7e1010" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/14743218" id="d7e1013" name="d7e1013" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">22</span> <a name="b22-ijo-41-02-0611" id="b22-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1019" id="d7e1019" shape="rect">
<!-- named anchor --></a>Liu L, Tommasi S, Lee DH, Dammann R and
Pfeifer GP: Control of microtubule stability by the RASSF1A tumor
suppressor. Oncogene. 22:8125–8136. 2003. <a target="xrefwindow" href="http://dx.doi.org/10.1038/sj.onc.1206984" id="d7e1021" name="d7e1021" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Control%20of%20microtubule%20stability%20by%20the%20RASSF1A%20tumor%20suppressor" id="d7e1024" name="d7e1024" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/14603253" id="d7e1027" name="d7e1027" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">23</span> <a name="b23-ijo-41-02-0611" id="b23-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1032" id="d7e1032" shape="rect">
<!-- named anchor --></a>Whang YM, Park KH, Jung HY, Jo UH and Kim
YH: Microtubule-damaging agents enhance RASSF1A-induced cell death
in lung cancer cell lines. Cancer. 115:1253–1266. 2009. <a target="xrefwindow" href="http://dx.doi.org/10.1002/cncr.24113" id="d7e1034" name="d7e1034" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Microtubule-damaging%20agents%20enhance%20RASSF1A-induced%20cell%20death%20in%20lung%20cancer%20cell%20lines" id="d7e1037" name="d7e1037" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/19156899" id="d7e1040" name="d7e1040" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">24</span> <a name="b24-ijo-41-02-0611" id="b24-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1045" id="d7e1045" shape="rect">
<!-- named anchor --></a>Reu FJ, Bae SI, Cherkassky L, et al:
Overcoming resistance to interferon-induced apoptosis of renal
carcinoma and melanoma cells by DNA demethylation. J Clin Oncol.
24:3771–3779. 2006. <a target="xrefwindow" href="http://dx.doi.org/10.1200/JCO.2005.03.4074" id="d7e1047" name="d7e1047" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Overcoming%20resistance%20to%20interferon-induced%20apoptosis%20of%20renal%20carcinoma%20and%20melanoma%20cells%20by%20DNA%20demethylation" id="d7e1050" name="d7e1050" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/16801630" id="d7e1053" name="d7e1053" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">25</span> <a name="b25-ijo-41-02-0611" id="b25-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1058" id="d7e1058" shape="rect">
<!-- named anchor --></a>Reu FJ, Leaman DW, Maitra RR, et al:
Expression of RASSF1A, an epigenetically silenced tumor suppressor,
overcomes resistance to apoptosis induction by interferons. Cancer
Res. 66:2785–2793. 2006. <a target="xrefwindow" href="http://dx.doi.org/10.1158/0008-5472.CAN-05-2303" id="d7e1060" name="d7e1060" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Expression%20of%20RASSF1A,%20an%20epigenetically%20silenced%20tumor%20suppressor,%20overcomes%20resistance%20to%20apoptosis%20induction%20by%20interferons" id="d7e1063" name="d7e1063" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/16510600" id="d7e1066" name="d7e1066" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">26</span> <a name="b26-ijo-41-02-0611" id="b26-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1071" id="d7e1071" shape="rect">
<!-- named anchor --></a>Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
<a target="xrefwindow" href="http://dx.doi.org/10.1016/j.ejca.2008.10.026" id="d7e1073" name="d7e1073" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=New%20response%20evaluation%20criteria%20in%20solid%20tumours:%20revised%20RECIST%20guideline%20(version%201.1)" id="d7e1076" name="d7e1076" shape="rect">Google Scholar</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">27</span> <a name="b27-ijo-41-02-0611" id="b27-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1081" id="d7e1081" shape="rect">
<!-- named anchor --></a>Pallares J, Velasco A, Eritja N, et al:
Promoter hypermethylation and reduced expression of RASSF1A are
frequent molecular alterations of endometrial carcinoma. Mod
Pathol. 21:691–699. 2008. <a target="xrefwindow" href="http://dx.doi.org/10.1038/modpathol.2008.38" id="d7e1083" name="d7e1083" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Promoter%20hypermethylation%20and%20reduced%20expression%20of%20RASSF1A%20are%20frequent%20molecular%20alterations%20of%20endometrial%20carcinoma" id="d7e1086" name="d7e1086" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/18469797" id="d7e1089" name="d7e1089" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">28</span> <a name="b28-ijo-41-02-0611" id="b28-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1094" id="d7e1094" shape="rect">
<!-- named anchor --></a>Ateeq B, Unterberger A, Szyf M and Rabbani
SA: Pharmacological inhibition of DNA methylation induces
proinvasive and prometastatic genes in vitro and in vivo.
Neoplasia. 10:266–278. 2008.<a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/18320071" id="d7e1096" name="d7e1096" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">29</span> <a name="b29-ijo-41-02-0611" id="b29-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1101" id="d7e1101" shape="rect">
<!-- named anchor --></a>Liu Z, Wu J, Xie Z, et al: Quantification
of regional DNA methylation by liquid chromatography/tandem mass
spectrometry. Anal Biochem. 391:106–113. 2009. <a target="xrefwindow" href="http://dx.doi.org/10.1016/j.ab.2009.05.012" id="d7e1103" name="d7e1103" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Quantification%20of%20regional%20DNA%20methylation%20by%20liquid%20chromatography/tandem%20mass%20spectrometry" id="d7e1106" name="d7e1106" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/19442645" id="d7e1109" name="d7e1109" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">30</span> <a name="b30-ijo-41-02-0611" id="b30-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1114" id="d7e1114" shape="rect">
<!-- named anchor --></a>McGrogan BT, Gilmartin B, Carney DN and
McCann A: Taxanes, microtubules and chemoresistant breast cancer.
Biochim Biophys Acta. 1785:96–132. 2008.<a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/18068131" id="d7e1116" name="d7e1116" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">31</span> <a name="b31-ijo-41-02-0611" id="b31-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1121" id="d7e1121" shape="rect">
<!-- named anchor --></a>Caudle AS, Gonzalez-Angulo AM, Hunt KK, et
al: Predictors of tumor progression during neoadjuvant chemotherapy
in breast cancer. J Clin Oncol. 28:1821–1828. 2010. <a target="xrefwindow" href="http://dx.doi.org/10.1200/JCO.2009.25.3286" id="d7e1123" name="d7e1123" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Predictors%20of%20tumor%20progression%20during%20neoadjuvant%20chemotherapy%20in%20breast%20cancer" id="d7e1126" name="d7e1126" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/20231683" id="d7e1129" name="d7e1129" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">32</span> <a name="b32-ijo-41-02-0611" id="b32-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1134" id="d7e1134" shape="rect">
<!-- named anchor --></a>Coon JS, Marcus E, Gupta-Burt S, et al:
Amplification and overexpression of topoisomerase IIalpha predict
response to anthracycline-based therapy in locally advanced breast
cancer. Clin Cancer Res. 8:1061–1067. 2002.<a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/11948114" id="d7e1136" name="d7e1136" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">33</span> <a name="b33-ijo-41-02-0611" id="b33-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1142" id="d7e1142" shape="rect">
<!-- named anchor --></a>Gascoigne KE and Taylor SS: How do
anti-mitotic drugs kill cancer cells? J Cell Sci. 122:2579–2585.
2009. <a target="xrefwindow" href="http://dx.doi.org/10.1242/jcs.039719" id="d7e1144" name="d7e1144" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=How%20do%20anti-mitotic%20drugs%20kill%20cancer%20cells?" id="d7e1147" name="d7e1147" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/19625502" id="d7e1150" name="d7e1150" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">34</span> <a name="b34-ijo-41-02-0611" id="b34-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1155" id="d7e1155" shape="rect">
<!-- named anchor --></a>Gascoigne KE and Taylor SS: Cancer cells
display profound intra- and interline variation following prolonged
exposure to antimitotic drugs. Cancer Cell. 14:111–122. 2008.
<a target="xrefwindow" href="http://dx.doi.org/10.1016/j.ccr.2008.07.002" id="d7e1157" name="d7e1157" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Cancer%20cells%20display%20profound%20intra-%20and%20interline%20variation%20following%20prolonged%20exposure%20to%20antimitotic%20drugs" id="d7e1160" name="d7e1160" shape="rect">Google Scholar</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">35</span> <a name="b35-ijo-41-02-0611" id="b35-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1165" id="d7e1165" shape="rect">
<!-- named anchor --></a>Whang YM, Kim YH, Kim JS and Yoo YD:
RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell
cycle progression. Cancer Res. 65:3682–3690. 2005. <a target="xrefwindow" href="http://dx.doi.org/10.1158/0008-5472.CAN-04-2792" id="d7e1167" name="d7e1167" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=RASSF1A%20suppresses%20the%20c-Jun-NH2-kinase%20pathway%20and%20inhibits%20cell%20cycle%20progression" id="d7e1170" name="d7e1170" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/15867363" id="d7e1173" name="d7e1173" shape="rect">PubMed/NCBI</a></p>
</td></tr><tr><td class="ref-label" rowspan="1" colspan="1">
<p class="ref-label"><span class="label">36</span> <a name="b36-ijo-41-02-0611" id="b36-ijo-41-02-0611" shape="rect">
<!-- named anchor --></a></p>
</td><td class="ref-content" rowspan="1" colspan="1">
<p class="citation"><a name="d7e1178" id="d7e1178" shape="rect">
<!-- named anchor --></a>Allan LA and Clarke PR: Phosphorylation of
caspase-9 by CDK1/cyclin B1 protects mitotic cells against
apoptosis. Mol Cell. 26:301–310. 2007. <a target="xrefwindow" href="http://dx.doi.org/10.1016/j.molcel.2007.03.019" id="d7e1180" name="d7e1180" shape="rect">View Article</a> : <a target="xrefwindow" href="http://scholar.google.com/scholar_lookup?title=Phosphorylation%20of%20caspase-9%20by%20CDK1/cyclin%20B1%20protects%20mitotic%20cells%20against%20apoptosis" id="d7e1183" name="d7e1183" shape="rect">Google Scholar</a> : <a target="xrefwindow" href="http://www.ncbi.nlm.nih.gov/pubmed/17466630" id="d7e1186" name="d7e1186" shape="rect">PubMed/NCBI</a></p>
</td></tr></table>





</div>
						</div>

						<div>
						   
						</div>

						<div>
							
						</div>

						<div id="moreLikeThisDiv">
	
	<h4>Related Articles</h4>
	<ul style="list-style-type:disc" id="moreLikeThisUl" class="moreLikeThisClassFragment">
        
     </ul>
	          		
		
	</div>

						<div class="article_interactive">
							<ul class="article_icons">
								<li><a href="/10.3892/ijo.2012.1470/abstract"><img
										src="/resources/images/iconabstract.png" alt="Abstract" /></a></li>

								<li><a href="/10.3892/ijo.2012.1470?text=fulltext">
										<img src="/resources/images/iconarticle.png"
										title="View Full Article" />
								</a> </li>

								<li><a href="/10.3892/ijo.2012.1470/download"> <img
										src="/resources/images/icondownload.png"
										title="Download Article" />
								</a> </li>

							</ul>

							<!-- AddThis Button -->
							<ul
								class="article_sharing addthis_toolbox addthis_default_style addthis_32x32_style">

								

								

								

								<li><a
									class="at300b"
									href="https://twitter.com/intent/follow?screen_name=@IjOncology">
										<img src="/resources/images/twitter_32.png"
										alt="Twitter" />
								</a></li>

								

								

								

								
								<li><a class="addthis_button_facebook"></a></li>
								<li><a class="addthis_button_preferred_3"></a></li>
								<li><a class="addthis_button_preferred_4"></a></li>
								<li><a class="addthis_button_compact"></a></li>
							</ul>
						</div>
					</div>
				</div>

				<div class="journal_information">
					<!-- Duplicated from Journal to avoid caching issue if a fragment -->
					<div class="journal_details">
						<div>
							<img src="/ISSUE_IMAGES/ijo_41_2.jpg"
								alt="Journal Cover" />
						</div>
						
											
						
						<p class="bold">
							<span class="bold">August 2012</span> 
							<br/>
							<span>Volume 41 Issue 2</span>
						</p>
						<p>
							Print ISSN: <span>1019-6439</span><br />
							Online ISSN:<span>1791-2423</span><br />
						</p>

						<p>
							<a href="/myaccount/updateaccountdetails?etocUpdate=1">Sign
								up for eToc alerts</a>
						</p>

						<p>
							<a href="/var/library_recommendation_form.pdf">Recommend to
								Library</a>
						</p>
					</div>

					<div class="article_sidebar">
						<ul>
							<li class="sidebar_title">Article Options</li>
							<li class="sidebar_subtitle">Viewing Options</li>
							<li><a href="/10.3892/ijo.2012.1470/abstract">View
									Abstract</a></li>
							<li><a id="isFullTextVisible" href="/10.3892/ijo.2012.1470?text=fulltext">Full
									Text</a></li>
							<li><a id="downloadPDFURL" href="/10.3892/ijo.2012.1470/download">
									Download PDF </a> </li>


							<li>
								</li>

							<li class="sidebar_subtitle">Citations</li>
							<li><a href='#' class='osx'>Cite This Article</a></li>
							<li><a href="/downloadRisFile/10.3892/ijo.2012.1470">Download Citation</a></li>



							<li id="track_citation"><a href="/trackCitation/10.3892/ijo.2012.1470"
								title="If you would like to be notified via email each time this article is cited, please click on the link.">Create
									Citation Alert</a></li>
							<li id="remove_track_citation"><a href="/removeTrackCitation/10.3892/ijo.2012.1470"
								title="If you would like not to be notified via email each time this article is cited, please click on the link.">Remove
									Citation Alert</a></li>
							<li><a href="http://scholar.google.co.uk/scholar?hl=en&amp;q=related:http://www.spandidos-publications.com/10.3892/ijo.2012.1470">Cited
									By</a></li>
							<li class="sidebar_subtitle">Related Articles</li>
							<li><a href="#moreLikeThisDiv">on Spandidos Publications</a></li>
							<li class="sidebar_subtitle">Similar Articles</li>
							<li><a href="http://scholar.google.co.uk/scholar?hl=en&amp;q=related:http://www.spandidos-publications.com/10.3892/ijo.2012.1470">on
									Google Scholar</a></li>
							<li><a href="http://www.ncbi.nlm.nih.gov/pubmed?cmd=Link&amp;db=pubmed&amp;dbFrom=PubMed&amp;from_uid=23288&amp;holding=f1000,f1000m,isrctn">on
									Pub Med</a></li>
							<li class="sidebar_subtitle">Copyright</li>
							<li><a href="http://www.copyright.com/openurl.do?issn=1791-2423">&copy;
									Get Permissions</a></li>
						</ul>

						<ul class="fixed_width_scopus">

							<li class="sidebar_title"><a href="/ijo">Journal Metrics</a></li>
							<li>Impact
								Factor: <span class="impact_factor_font">5.65</span>
							</li>

							<li>Ranked
								<span class="impact_factor_font"></span>

								<span>Oncology</span> <br /> (total
								number of cites)
							</li>

							<li>
								CiteScore: <span class="impact_factor_font">8.2</span> 
							</li>

							<li>CiteScore
								Rank: <span class="impact_factor_font">Q1: #52/340</span> <span>Oncology</span> 
							</li>

							<li>
								Source Normalized Impact per Paper (SNIP): <span
								class="impact_factor_font">1.045</span>
								
							</li>
							<li>
								SCImago Journal Rank (SJR): <span class="impact_factor_font">1.405</span> 
							</li>
						</ul>
					</div>






					<div class="article_sidebar twitter-articles">
						<div>
							<a class="twitter-timeline" data-width="25" data-tweet-limit="5"
								href="https://twitter.com/IjOncology?ref_src=twsrc%5Etfw">Tweets
								by @IjOncology</a>
						</div>
						<div class="article-twitter-buttons">
							<a href="https://twitter.com/IjOncology?ref_src=twsrc%5Etfw"
								class="twitter-follow-button" data-show-screen-name="false"
								data-dnt="true" data-show-count="false">Follow @IjOncology</a>

						</div>
					</div>


					

					


					


					

					

					


					

				</div>


			</div>

		</div>





		<div class="wide">
	
	<div class="event fixed_width">
			<a id="downloadCancerStoryPdf"  class="staticContent" href="#">
					<img src="/resources/images/cancer_story_banner.jpg" alt="The Cancer Story" />
			</a>
				
				
		</div>
	
		<div class="event fixed_width">
				<a href="http://www.worldacademyofsciences.com/rome2020.html" class="staticContent">
				<img src="/resources/images/1st_conference.jpg" alt="International Symposium on Molecular Medicine Conference Banner" />
				</a>				
		</div>
		
				
		<div class="event fixed_width">
				<a href="/pages/conference" class="staticContent">
				<img src="/resources/images/conferencebanner.jpg" alt="World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner" />
				</a>					
		</div>
		
		<div class="event fixed_width">
				<a href="http://www.worldacademyofsciences.com/china2020.html" class="staticContent">
				<img src="/resources/images/3rd_conference.jpg" alt="28th International Symposium on Molecular Medicine" />
				</a>				
		</div>
		
		<div class="event fixed_width">
				<a href="http://www.worldacademyofsciences.com/chile2020.html" class="staticContent">
				<img src="/resources/images/2nd_conference.jpg" alt="International Symposium on Molecular Medicine Conference Banner" />
				</a>				
		</div>	
		
		
		<div class="event fixed_width">
				<a href="http://www.worldacademyofsciences.com" class="staticContent">
				<img src="/resources/images/world_of_academy_banner.jpg" alt="World Academy Of Sciences Banner" />
				</a>				
		</div>
	
			
			
		
		
	</div>
		<div class="footer wide">
	    
		 <div id="navbar" align="center" class="fixed_width footer">
			 			 
		 <div class="gdpr_table" >
			<div class="gdpr_row">
				<div class="gdpr_cell_header">
					<p><strong>This site uses cookies</strong></p>
				</div>		
					
			</div>
			<div class="gdpr_row">
				<div class="gdpr_cell_text">
					<p>You can change your cookie settings at any time by following the instructions in our <a	href="https://www.spandidos-publications.com/pages/cookies"	target="_blank">Cookie Policy</a>. To find out more, you may read our
					<a	href="https://www.spandidos-publications.com/pages/privacy"	target="_blank">Privacy Policy</a>. 
					<a href="#"  id="gdprButton"	class="gdpr_button">I agree</a>	
					</p>
				</div>			
						
			</div>
		</div>
			  
		</div>


		<div class="footer fixed_width">
				<div class="footer_copyright">
						<p  id="rightsReserved">0 </p>
			</div>
			
			
			<div class="footer_links">
				<ul class="social">
					<li>
						<a href="https://twitter.com/intent/follow?screen_name=@SpandidosP">  <img src="/resources/images/twitter.png" alt="Twitter"/> </a>             
					</li>
					<li>
						<a href="http://www.linkedin.com/company/2926613" title="Follow us on LinkedIn"><img src="/resources/images/linkedin.png" alt="LinkedIn"/></a>
					</li>
					<li>
						<a href="https://www.facebook.com/SpandidosPublications" title="Likes us on Facebook"><img src="/resources/images/facebook.png" alt="Facebook"/></a>
					</li>
					
				</ul>
				<ul class="footer_nav">
					<li><a href="/pages/about" id="about" class="staticContent">About</a></li>
					<li>
						<a href="/pages/contact" id="Contact" class="staticContent">Contact</a>
					</li>
					<li><a href="/pages/help">Help</a></li>
					<li><a href="/pages/cookies">Cookie Policy</a></li>
					<li><a href="/pages/privacy">Privacy Policy</a></li>

				</ul>
			</div>
		</div>
		
		 
		<div id="growl" class="bottom-left"></div>
		
	<!--Add the following script at the bottom of the web page (before </body></html>)-->
<script type="text/javascript">function add_chatwidget(){var hccid=66058258;var nt=document.createElement("script");nt.async=true;nt.src="https://www.mylivechat.com/chatwidget.aspx?hccid="+hccid;var ct=document.getElementsByTagName("script")[0];ct.parentNode.insertBefore(nt,ct);}
add_chatwidget();</script>
		
		<script src="/resources/js/jquery-3.4.1.min.js" type="text/javascript"></script>
		<script src="/resources/js/jquery-migrate-3.1.0.min.js" type="text/javascript"></script>

		<script src="/resources/js/app.js" type="text/javascript"></script>
		<script src="/resources/js/js.cookie-2.2.0.min.js"></script>
		
		 <script>
  		  	/*<![CDATA[*/
  		  	  $(document).ready(function () {
  		  		  		  		
  		  		if(null){  		  			
  		  		
  		  			sessionStorage.setItem("orcid_logout_uri", null);
  		  		}
  	
  		  		$("#rightsReserved").html('Copyright &copy; Spandidos Publications ' +(new Date()).getFullYear()+'. All rights reserved.');
  		  	});
  		  		
			 /*]]>*/
   		 </script>
		
		<script type="text/javascript">
			(function(b, o, i, l, e, r) {
				b.GoogleAnalyticsObject = l;
				b[l] || (b[l] =
						function() {
							(b[l].q = b[l].q || []).push(arguments)
						});
				b[l].l = +new Date;
				e = o.createElement(i);
				r = o.getElementsByTagName(i)[0];
				e.src = '//www.google-analytics.com/analytics.js';
				r.parentNode.insertBefore(e, r)
			}(window, document, 'script', 'ga'));
			ga('create', 'UA-45385578-1');
			ga('send', 'pageview');
		</script>
			<script async="async" crossorigin="anonymous" src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
		<!-- Google Code for English -->
		<!-- Remarketing tags may not be associated with personally identifiable information or placed on pages related to sensitive categories. For instructions on adding this tag and more information on the above requirements, read the setup guide: google.com/ads/remarketingsetup -->
		<script type="text/javascript">
			/* <![CDATA[ */
			var google_conversion_id = 982681053;
			var google_conversion_label = "ewoHCKvwggoQ3YvK1AM";
			var google_custom_params = window.google_tag_params;
			var google_remarketing_only = true;
			/* ]]> */
		</script>
		<script type="text/javascript" src="//www.googleadservices.com/pagead/conversion.js">
		</script>
		
		<noscript>
			<div style="display:inline;">
				<img height="1" width="1" style="border-style:none;" alt="" src="//googleads.g.doubleclick.net/pagead/viewthroughconversion/982681053/?value=1.00&amp;label=ewoHCKvwggoQ3YvK1AM&amp;guid=ON&amp;script=0"/>
			</div>
		</noscript>
	<script>
    /*<![CDATA[*/
    	
    	$( "#gdprButton" ).click(function() {
    		Cookies.set('spandidos-gdpr', 'true', { expires: 365 });
   		 	$('#navbar').hide();
   		   $(window).scroll(function() {      		
         	 $('#navbar').hide();      		  
         	});
		});
		
		$('#logout').click(function() { 					
					
			forceSignOut();					
		});
    	
    	function forceSignOut(){
    		
    		let ocridlogouturl = sessionStorage.getItem("orcid_logout_uri");    		
    		ocridlogouturl = removeDoubleQuote(ocridlogouturl);    		
    		
    		$.ajax({
                url: ocridlogouturl,
                dataType: 'jsonp',
                success: function(result,status,xhr) {
                    console.log("Logged In: " + result.loggedIn);
                },
                error: function (xhr, status, error) {
                	console.log(status);
                }
            });
    	}
    	
    	function removeDoubleQuote(url){
    		return url.replace(/['"]+/g, '');
    	}
    
    	//Show guest editors list only if it has a person
        $(document).ready(function () {	
        	
	  		$( ".guestEditors" ).each(function() {
	  			
	  			if($(this).children().length > 0) {
		  			$(this).parent().show();
		  		}
	  		 
	  		});
	  	});
	/*]]>*/
	 </script>
		
	</div>

		<script type='text/javascript'
			src="/resources/js/jquery.simplemodal.js"></script>
		<script type='text/javascript' src="/resources/js/osx.js"></script>
		<!-- modal content -->
		<div id="osx-modal-content">
			<div id="osx-modal-title">Copy and paste a formatted citation</div>
			<div class="close">
				<a href="#" class="simplemodal-close">x</a>
			</div>
			<div id="osx-modal-data">
				<div class="inline">
					<div>
						<div class="citationFormat">Spandidos Publications style</div>
						<div class="citation">Gil EY, Jo UH, Jeong H, Whang YM, Woo OH, Cho KR, Seo JH, Kim A, Lee ES, Koh I, Koh I, et al: Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. Int J Oncol 41: 611-620, 2012</div>
					</div>
					<div>
						<div class="citationFormat">APA</div>
						<div class="citation">Gil, E.Y., Jo, U.H., Jeong, H., Whang, Y.M., Woo, O.H., Cho, K.R. ... Park, K.H. (2012). Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer. International Journal of Oncology, 41, 611-620. https://doi.org/10.3892/ijo.2012.1470</div>
					</div>
					<div>
						<div class="citationFormat">MLA</div>
						<div class="citation">Gil, E. Y.,  Jo, U. H.,  Jeong, H.,  Whang, Y. M.,  Woo, O. H.,  Cho, K. R.,  Seo, J. H.,  Kim, A.,  Lee, E. S.,  Koh, I.,  Kim, Y. H.,  Park, K. H.&quot;Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer&quot;. International Journal of Oncology 41.2 (2012): 611-620.</div>
					</div>
					<div>
						<div class="citationFormat">Chicago</div>
						<div class="citation">Gil, E. Y.,  Jo, U. H.,  Jeong, H.,  Whang, Y. M.,  Woo, O. H.,  Cho, K. R.,  Seo, J. H.,  Kim, A.,  Lee, E. S.,  Koh, I.,  Kim, Y. H.,  Park, K. H.&quot;Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer&quot;. International Journal of Oncology 41, no. 2 (2012): 611-620. https://doi.org/10.3892/ijo.2012.1470</div>
					</div>
				</div>
			</div>
		</div>

		<!-- Used to generate counter -->
		<input type="hidden" id="doid" value="10.3892/ijo.2012.1470" />
		<input type="hidden" id="toa"
			value="F" /> <input
			type="hidden" id="ptvstatus" value="F12" />
		<input type="hidden" id="user_id"
			value="" />
		<input type="hidden" id="journal_id" value="ijo" /> <input
			type="hidden" id="alert_track_citation_message"
			value="" />

		<script src="/resources/js/counter.js"></script>
		<script type='text/javascript'
			src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'></script>
		<script type="text/javascript">var addthis_config = addthis_config||{}; addthis_config.data_track_addressbar = false;</script>
		<script type="text/javascript"
			src="https://s7.addthis.com/js/300/addthis_widget.js#pubid=ra-4fe476482ba42f68"></script>

		<script async="async" crossorigin="anonymous"
			src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
		<script src="https://code.jquery.com/ui/1.11.1/jquery-ui.min.js"></script>
		<script src="https://cdn.tiny.cloud/1/560gz528beukra3kb9syq7iido8yu0in5iysfds42lt1q48q/tinymce/4.5.7-72/tinymce.min.js" type="text/javascript"></script> 


		<!-- Add fancyBox main JS and CSS files -->
		<script type="text/javascript"
			src="/resources/js/jquery.fancybox.js"></script>
		<script src="/resources/js/jquery.jgrowl.min.js"
			type="text/javascript"></script>

		<script>
    /*<![CDATA[*/
    	var articleId = 23288;
        $(document).ready(function () {
        	$(".rightsReservedCrossref").html((new Date()).getFullYear()-1);
        	        	
        	$("html, body").animate({"scrollTop":$("#titleId").offset().top}, 1000); 
        	
        	if(!Cookies.get('spandidos-gdpr')) {
        	 $('#navbar').show();
    		
        	$(window).scroll(function() {
          		 if($(window).scrollTop() + $(window).height() > $(document).height() - 50) {
          			 $('#navbar').hide();
          		   }
          		 if($(window).scrollTop() + $(window).height() <= $(document).height() - 50) {
          			 $('#navbar').show();
          		   }
          		});
    		 }
        	
            /* citation */
            
            $('#citation').on('click', '.citedBy', function (e) {
                e.preventDefault();
				if ($('#citations').html() != "") {
	                $("#citationDiv").show();				
				}
            });
            
            $('#citationAllArticlesId').on('click', '.citedBy', function (e) {
                e.preventDefault();
				if ($('#citations').html() != "") {
	                $("#citationDiv").show();				
				}
            });
            
            
            var urlTotalCount = $(".citedByCountId").attr('href');
            $.ajax({url: urlTotalCount, cache: false, success: function (result) {

	                if (result) {
	                	
	                	var count = result;
	                	
	                	if (count > 0) {
		                    $("#citationDiv").hide();
	    	                //$("#citations").html(result);
	        	        } else {
	        	        	$("#citedByIdViewArticles").text("No Articles");
	        	        }
	                	$("#citationCount").html(count);
	                	makeCitationsVisible();
	                } else {
	                	$("#citationCount").html(0);
	                	$("#citedByIdViewArticles").text("No Articles");
	                }
            	}

            });
            
            var url = $(".citedBy").attr('href');
            $.ajax({url: url, cache: false, success: function (result) {

                if (result) {
                	var items = $(result).children();
                	var count = items.length;
                	if (count > 0) {
	                    $("#citationDiv").hide();
    	                $("#citations").html(result);
    	                
    	                $("#citedByIdViewArticles").text("View Articles"); 
    	                
        	        }
                	
                	
                	//$("#citationCount").html(count);
                	makeCitationsVisible();
	                } else {
	                	//$("#citationCount").html(0);
	                	 $("#citedByIdViewArticles").text("No Articles"); 
	                }
            	}
            
            
            
            
            }); 
       
            
           var urlMoreLikeThis = $(".moreLikeThis").attr('href');
            $.ajax({url: urlMoreLikeThis, cache: false,success: function(result){
            	$("#moreLikeThisDiv .moreLikeThisClassFragment").html( $("#moreLikeThisUl", result) );   
		    }});

            /* Simple image gallery. Uses default settings */
            $('a.fancybox').fancybox({
                maxWidth: 1000,
                maxHeight: 800,
                helpers: {
                    title: {
                        type: 'inside'
                    }
                }
            });
        });
        
	var doi= $("#doid").val().split("/")[1];
	     	 $.ajax({
        	    type: "GET",
        	    url: "/retrieveArticleDownloadsAndViews/" +  doi, 
        	    dataType: "json",
        	    success: function(data, textStatus, jqXHR) {
        	   
       
        	    if (data!=null) {	    			
	    		  $("#postFullArticleViews").html(data.fullTextCount);
	    		  $("#postArticleDownloads").html(data.pdfCount);
	   			  $("#postPMCFullArticleViews").html(data.pmcFullTextCount);
	   			  $("#postArticlePMCDownloads").html(data.pmcPdfCount);
	   			  $("#postTotalFullArticleViews").html(data.totalFullTextCount);
	   			  $("#postTotalArticleDownloads").html(data.totalPdfCount);
	    	   	}
	    		else  {
	   			  $("#postFullArticleViews").html(0);
	   			  $("#postArticleDownloads").html(0);
	   			  $("#postPMCFullArticleViews").html(0);
	   			  $("#postArticlePMCDownloads").html(0);
	   			  $("#postTotalFullArticleViews").html(0);
	   			  $("#postTotalArticleDownloads").html(0);
	   	      }
		    },
        	   error: function (jqXHR, textStatus, errorThrown) {
		    }
		});
        
	     	 
	    function makeCitationsVisible(){
	    	try{
        		var searchAttribute = $(location).attr('search');
        		if (searchAttribute == '?citations' ) {
        			if ($('#citations').html() != "") {
	                	$("#citationDiv").show();				
					}
        		}
        	} catch (err) {
        		
        	}
	    }
	    
	    $('#toggleSM').click(function() {
	   		 $('.toggleSM').toggle();
		 });
	    
	   
	    $('#toggleSF').click(function() {
	   		 $('.toggleSF').toggle();
		 });
	    
	    
	    
	    $('#toggleMostCitedDimensions').click(function() {
	   		$('.toggleMostCitedDimensions').toggle();
		});
        
        $('#toggleMostCitedCrossRef').click(function() {
	   		$('.toggleMostCitedCrossRef').toggle();
		});
        
        $('#toggleRef').click(function() {
	   		 $('.toggleRef').toggle();
		 });
        
        $('#toggleFig').click(function() {
	   		 $('.toggleFig').toggle();
		 });
        
        var userId= $("#user_id").val();  
        if(userId!='') {
        $.ajax({
    		type: "GET",
   	   		 url: "/retrieveUserSelectedArticle/" + userId +"/" +  doi, 
   	    	dataType: "json",
   	    	success: function(data, textStatus, jqXHR) {
	  		 if (data) {
   				$('#track_citation').css("display", "none"); ;
   				$('#remove_track_citation').css("display", "block");
   	   		 }
   			else  {
   				$('#track_citation').css("display", "block") ;
   				$('#remove_track_citation').css("display", "none");
  	      	}
	   	 	},
   	   		error: function (jqXHR, textStatus, errorThrown) {
	   		 }    	
		});
        } else {
        	$('#track_citation').css("display", "block");
				$('#remove_track_citation').css("display", "none");
        }
        
        $(window).bind("load", function() {
        	var messsageTrackCitation= $('#alert_track_citation_message');	 
        	
        	if(messsageTrackCitation.length>0  && messsageTrackCitation.val()!=null && messsageTrackCitation.val()!='') {	         		
        		$.jGrowl( messsageTrackCitation.val());
        	 }
         });             
              
        /*]]>*/
    </script>


	</div>
	<!-- End Wrapper -->
</body>

</html>